JP2004359646A - New azole derivative with antimycotic activity - Google Patents
New azole derivative with antimycotic activity Download PDFInfo
- Publication number
- JP2004359646A JP2004359646A JP2003163358A JP2003163358A JP2004359646A JP 2004359646 A JP2004359646 A JP 2004359646A JP 2003163358 A JP2003163358 A JP 2003163358A JP 2003163358 A JP2003163358 A JP 2003163358A JP 2004359646 A JP2004359646 A JP 2004359646A
- Authority
- JP
- Japan
- Prior art keywords
- group
- difluoro
- substituent
- difluorophenyl
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007980 azole derivatives Chemical class 0.000 title claims abstract description 41
- 230000001857 anti-mycotic effect Effects 0.000 title abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 150000002924 oxiranes Chemical class 0.000 claims description 9
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 8
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 201000009862 superficial mycosis Diseases 0.000 abstract description 6
- 206010052366 systemic mycosis Diseases 0.000 abstract description 6
- -1 methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy Chemical group 0.000 description 126
- 150000001875 compounds Chemical class 0.000 description 102
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 94
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- 239000013078 crystal Substances 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- 238000002844 melting Methods 0.000 description 42
- 230000008018 melting Effects 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 239000003921 oil Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 17
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 241000233866 Fungi Species 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 239000007810 chemical reaction solvent Substances 0.000 description 6
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229960004884 fluconazole Drugs 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical class [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 4
- 229910001863 barium hydroxide Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- FRDZGSBXKJXGNR-HTQZYQBOSA-N (1r,2r)-2-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN(C)[C@@H]1CCCC[C@H]1N FRDZGSBXKJXGNR-HTQZYQBOSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 125000000676 alkoxyimino group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- MGHBDQZXPCTTIH-UHFFFAOYSA-N 1-bromo-2,4-difluorobenzene Chemical compound FC1=CC=C(Br)C(F)=C1 MGHBDQZXPCTTIH-UHFFFAOYSA-N 0.000 description 2
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 2
- GVCAWQUJCHZRCB-UHFFFAOYSA-N ethyl 2-chloro-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Cl GVCAWQUJCHZRCB-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- WGOBPPNNYVSJTE-UHFFFAOYSA-N 1-diphenylphosphanylpropan-2-yl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)CP(C=1C=CC=CC=1)C1=CC=CC=C1 WGOBPPNNYVSJTE-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- YGWFXCNFJPSDPX-UHFFFAOYSA-N 2-(4-bromophenoxy)-2,2-difluoroacetic acid Chemical compound OC(=O)C(F)(F)OC1=CC=C(Br)C=C1 YGWFXCNFJPSDPX-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- BBFABBPRTRSHIP-UHFFFAOYSA-N 2-bromo-1-(2,4-difluorophenyl)-2,2-difluoroethanone Chemical compound FC1=CC=C(C(=O)C(F)(F)Br)C(F)=C1 BBFABBPRTRSHIP-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- AEMFKWCHSLHKGS-UHFFFAOYSA-N C(C1=CC=CC=C1)C(CN1N=CN=C1)O Chemical compound C(C1=CC=CC=C1)C(CN1N=CN=C1)O AEMFKWCHSLHKGS-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WRZAEYPMXPLVJL-UHFFFAOYSA-N FC(C1(c2ccccc2)OC1)(O[AlH2])F Chemical compound FC(C1(c2ccccc2)OC1)(O[AlH2])F WRZAEYPMXPLVJL-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N binaphthyl group Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- QVQGTNFYPJQJNM-UHFFFAOYSA-N dicyclohexylmethanamine Chemical compound C1CCCCC1C(N)C1CCCCC1 QVQGTNFYPJQJNM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- VJYFKVYYMZPMAB-UHFFFAOYSA-N ethoprophos Chemical compound CCCSP(=O)(OCC)SCCC VJYFKVYYMZPMAB-UHFFFAOYSA-N 0.000 description 1
- RQBZGGGMOLACAJ-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(3-fluorophenoxy)acetate Chemical compound CCOC(=O)C(F)(F)OC1=CC=CC(F)=C1 RQBZGGGMOLACAJ-UHFFFAOYSA-N 0.000 description 1
- MOCXDOZCWMKGRG-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(4-fluorophenoxy)acetate Chemical compound CCOC(=O)C(F)(F)OC1=CC=C(F)C=C1 MOCXDOZCWMKGRG-UHFFFAOYSA-N 0.000 description 1
- DRZSOYQFGXVGCK-UHFFFAOYSA-N ethyl 2-(4-bromophenoxy)-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)OC1=CC=C(Br)C=C1 DRZSOYQFGXVGCK-UHFFFAOYSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- ZVYXEXAXXWINEH-UHFFFAOYSA-N n,n-diethyl-2-hydroxybenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC=C1O ZVYXEXAXXWINEH-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- BFMKBYZEJOQYIM-UCGGBYDDSA-N tert-butyl (2s,4s)-4-diphenylphosphanyl-2-(diphenylphosphanylmethyl)pyrrolidine-1-carboxylate Chemical compound C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 BFMKBYZEJOQYIM-UCGGBYDDSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、優れた抗真菌作用と高い安全性を有するアゾール誘導体又はその塩、その製造中間体、及びそれを有効成分として含有する医薬に関する。
【0002】
【従来の技術】
真菌症には、各種白癬、頑癬、乾癬、皮膚カンジダ症等に代表される表在性真菌症と、真菌性髄膜炎、真菌性呼吸器感染症、真菌血症、尿路真菌症等に代表される深在性真菌症とがある。このうちカンジダ症、アスペルギルス症等の深在性真菌症は、癌化学療法剤や免疫抑制剤の繁用、HIV感染等による生体内免疫の低下等により、特に近年増加の傾向にあり、これらの菌に有効な薬剤が望まれている。
【0003】
しかし、アスペルギルス菌及びカンジダ菌に有効な薬剤としては、従来、アムホテリシンBや、アゾール系化合物のフルコナゾール、イトラコナゾール等が知られているが、未だ僅少である。また、これらの薬剤は、いずれも安全性又は抗真菌作用の点で問題があり、アスペルギルス菌及びカンジダ菌に有効な抗真菌剤が望まれている。現在、より有効なアゾール系化合物の開発が行われており、例えば、2,2−ジフルオロ−2−アルキルチオメチル基、2,2−ジフルオロ−2−アルキルスルフィニルメチル基又は2,2−ジフルオロ−2−アルキルスルホニルメチル基を有するトリアゾール誘導体が知られているが(特許文献1〜3参照)、必ずしも十分に満足し得るものではない。
【0004】
【特許文献1】
特開平9−227531号公報
【特許文献2】
特開平11−240871号公報
【特許文献3】
特開平11−279160号公報
【0005】
【発明が解決しようとする課題】
従って、本発明は、安全性が高く深在性真菌症及び表在性真菌症に有効な抗真菌活性を有する新規アゾール誘導体を提供することを目的とする。
【0006】
【課題を解決するための手段】
斯かる実情において、本発明者らは、数多くのアゾール誘導体又はその塩を合成し、その抗真菌作用について鋭意検討を行った結果、下記一般式(1)で表される新規アゾール誘導体又はその塩が、深在性真菌症及び表在性真菌症の原因菌に対して優れた抗菌活性を示し、更にフルコナゾール耐性菌に対しても抗菌活性を示し、しかも毒性が低く、CYP(チトクロームP450)阻害作用が弱いという安全性も高いことを見出し、本発明を完成させた。
【0007】
すなわち、本発明は、下記一般式(1):
【0008】
【化6】
【0009】
[式中、Xは、N又はCHを示し;Arは、置換基を有することもあるフェニル基又は置換基を有することもある芳香族複素環基を示す。]で表されるアゾール誘導体又はその塩、及びこれらの製造中間体、並びにこられの化合物の製造方法を提供するものである。
【0010】
本発明はまた、上記一般式(1)で表されるアゾール誘導体又はその塩を有効成分とする医薬を提供するものである。
【0011】
【発明の実施の形態】
本発明のアゾール誘導体は、前記一般式(1)で示されるものであるが、式中、Arで示されるフェニル基が有することもある置換基(R)としては、ハロゲン原子、ハロゲノC1−6アルキル基、C1−6アルキル基、C1−6アルコキシ基、ニトロ基、ヒドロキシ基、カルボキシ基、シアノ基、置換基を有することもあるC2−6アルケニル基、置換基を有することもあるC2−6アルキニル基、置換基を有することもあるフェニル基、C7−26アラルキルオキシ基、C1−6アルキレンジオキシ基、置換基を有することもあるアミノ基、置換基を有することもあるカルバモイル基、置換基を有することもあるスルホニルアミノ基、置換基を有することもある4〜7員の脂環式複素環基、置換基を有することもある芳香族複素環基、C1−6アルコキシイミノ基等が挙げられる。
【0012】
ハロゲン原子としては、F、Cl、Br、I等が挙げられる。
【0013】
ハロゲノC1−6アルキル基、C1−6アルキル基等におけるC1−6アルキルとしては、C1−6の直鎖又は分岐鎖のアルキルが挙げられる。C1−6の直鎖アルキルとしては、メチル、エチル、n−プロピル、n−ブチル等が挙げられ、分岐鎖アルキルとしては、イソプロピル、イソブチル、sec−ブチル、tert−ブチル等が挙げられる。ハロゲノC1−6アルキル基としては、フルオロメチル基、クロロメチル基、ブロモメチル基、フルオロエチル基、クロロエチル基、ブロモエチル基等が挙げられる。
【0014】
C1−6アルコキシ基、C1−6アルコキシイミノ基等におけるC1−6アルコキシとしては、C1−6の直鎖又は分岐鎖のアルコキシが挙げられ、具体的には、メトキシ、エトキシ、n−プロポキシ、イソプロピルオキシ、n−ブトキシ、イソブチルオキシ、sec−ブチルオキシ、tert−ブチルオキシ等が挙げられる。C1−6アルコキシイミノ基としては、具体的には、N−メトキシイミノ基、N−エトキシイミノ基等が挙げられる。
【0015】
置換基を有することもあるフェニル基としては、無置換のフェニル基の他に、上記C1−6アルキル基、上記C1−6アルコキシ基で置換されたフェニル基が挙げられ、具体的には、メチルフェニル基、エチルフェニル基、メトキシフェニル基、エトキシフェニル基等が挙げられる。
【0016】
置換基を有することもあるC2−6アルケニル基としては、無置換のC2−6アルケニル基の他に、上記C1−6アルキル基、上記C1−6アルコキシ基、C1−6アルコキシカルボニル基等で置換されたC2−6アルケニル基が挙げられる。C1−6アルコキシカルボニル基としては、上記C1−6アルキル基を有するものであり、具体的には、メトキシカルボニル基、エトキシカルボニル基等が挙げられる。当該C2−6アルケニル基としては、具体的には、ビニル基、2−プロペニル基、2−メトキシカルボニルエテニル基、2−エトキシカルボニルエテニル基等が挙げられる。
【0017】
置換基を有することもあるC2−6アルキニル基としては、無置換のC2−6アルキニル基の他に、上記C1−6アルキル基、上記C1−6アルコキシ基、C6−20アリール基等で置換されたC2−6アルキニル基が挙げられる。C6−20アリール基としては、具体的には、フェニル基、ナフチル基等が挙げられる。当該C2−6アルキニル基としては、2−フェニルエチニル基が好ましい。
【0018】
C7−26アラルキルオキシ基のC7−26アラルキルは、上記C1−6アルキルと上記C6−20アリール基とからなるものを意味し、C7−26アラルキルオキシ基の具体例としては、ベンジルオキシ基、フェネチルオキシ基等が挙げられる。
【0019】
C1−6アルキレンジオキシ基のC1−6アルキレンとしては、メチレン及びエチレンが挙げられ、C1−6アルキレンジオキシ基としては、メチレンジオキシ基が好ましい。
【0020】
置換基を有することもあるアミノ基としては、無置換のアミノ基の他に、上記C1−6アルコキシ基で更に置換されてなるアルキル基で置換されたアミノ基が挙げられる。具体的には、メトキシメチルアミノ基、2−メトキシエチルアミノ基、3−メトキシプロピルアミノ基、エトキシメチルアミノ基、2−エトキシエチルアミノ基、3−エトキシプロピルアミノ等が挙げられ、3−メトキシプロピルアミノ基が好ましい。
【0021】
置換基を有することもあるカルバモイル基としては、無置換のカルバモイル基の他に、上記のC1−6アルキル基、上記C7−26アラルキルオキシ基、上記C1−6アルキル基で更に置換されたフェニル基等で置換されたカルバモイル基が挙げられ、具体的には、ベンジルオキシカルバモイル基、4−メチルフェニルカルバモイル基等が挙げられる。
【0022】
置換基を有することもあるスルホニルアミノ基上の置換基としては、上記のカルバモイル基が有することもある置換基と同様なものが挙げられ、メチルフェニル基及びエチルフェニル基が好ましく、メチルフェニル基がより好ましい。当該スルホニルアミノ基としては、メチルフェニルスルホニルアミノ基が好ましい。
【0023】
置換基を有することもある4〜7員の脂環式複素環基における脂環式複素環基としては、ピロリジニル基、イミダゾリジニル基、ピペリジル基、ピペラジニル基、ピラゾリジニル基、モルホリニル基、チオモルホリニル基、オキサゾリジニル基等が挙げられる。脂環式複素環基上の置換基としては、オキソ基、下記C1−6アルコキシカルボニル基、上記置換基を有することもあるフェニル基、ハロゲン原子、上記ハロゲノC1−6アルキル基、上記C1−6アルキル基、上記C1−6アルコキシ基、ヒドロキシ基、アミノ基、シアノ基、カルバモイル基、カルボキシル基、ニトロ基、スルホンアミド基等が挙げられ、オキソ基、下記C1−6アルコキシカルボニル基及び上記置換基を有することもあるフェニル基が好ましい。置換基の数としては、1〜3個が好ましい。C1−6アルコキシカルボニル基としては、メトキシカルボニル基、エトキシカルボニル基及びtert−ブトキシカルボニル基が好ましく、tert−ブトキシカルボニル基がより好ましい。フェニル基上の置換基としては、上記C1−6アルキル基、C1−6アルコキシ基、ハロゲン原子及びニトロ基が好ましく、メトキシ基、フッ素原子、塩素原子及びニトロ基がより好ましい。フェニル基上の置換基の数は、1〜5個であることが好ましく、1〜3個がより好ましい。
【0024】
置換基を有することもある芳香族複素環基の芳香族複素環基としては、ピロリル基、フリル基、チエニル基、ピラゾリル基、イソチアゾリル基、イミダゾリル基、オキサゾリル基、チアゾリル基、トリアゾリル基、ピリジル基、ピリダジニル基、ピラジニル基、ピリミジニル基等が挙げられ、ピラゾリル基、イミダゾリル基及びトリアゾリル基が好ましい。芳香族複素環基上の置換基としては、上記脂環式複素環基が有することもある置換基と同様なものが挙げられ、トリアゾリル基はオキソ基で置換されていることが好ましい。
【0025】
上記Arで示される置換基を有することもあるフェニル基上の置換基の数は1〜3個が好ましい。
【0026】
また、一般式(1)のArで示される置換基を有することもある芳香族複素環基の芳香族複素環基としては、ピロリル基、フリル基、チエニル基、ピラゾリル基、イソチアゾリル基、イミダゾリル基、オキサゾリル基、チアゾリル基、トリアゾリル基、ピリジル基、ピリダジニル基、ピラジニル基、ピリミジニル基、ベンゾピロリル基、ベンゾフラニル基、ベンゾチエニル基、ベンゾピラゾリル基、ベンゾイソキサゾリル基、ベンゾイソチアゾリル基、ベンゾイミダゾリル基、ベンゾオキサゾリル基、ベンゾチアゾリル基、キノリル基、イソキノリル基、シンノリニル基、フタラジニル基、キナゾリニル基、キノキサリニル基等が挙げられる。上記芳香族複素環基上の置換基としては、Arで示される置換基を有することもあるフェニル基上の置換基と同様なものが挙げられ、置換基の数は1〜3個が好ましい。
【0027】
一般式(1)で示されるArとしては、置換基を有することもあるフェニル基又は無置換のピリジル基が好ましく、置換基を有することもあるフェニル基がより好ましく、下記表1記載の化合物番号1〜46に相当する基が特に好ましい。
【0028】
一般式(1)で表されるアゾール誘導体において、三級水酸基が結合する炭素原子と同一の炭素原子に結合するフェニル基に置換する2個のフッ素原子の位置は、2,4−又は2,5−であることが好ましく、2,4−であることがより好ましい。
【0029】
以下に、一般式(1)で表される本発明の化合物の好ましい具体例を示す。
【0030】
【表1】
【0031】
【表2】
【0032】
【表3】
【0033】
本発明の化合物(1)の塩としては、薬学的に許容される塩であれば特に制限されないが、酸付加塩、例えば塩酸塩、硝酸塩、臭化水素酸塩、p−トルエンスルホン酸塩、メタンスルホン酸塩、フマル酸塩、コハク酸塩、乳酸塩等が挙げられる。
【0034】
本発明の化合物(1)又はその塩は、不斉炭素原子に基づく立体異性体が存在するが、本発明にはこれらのいずれの異性体も、またラセミ体等の異性体混合物も含まれる。また、アゾール誘導体又はその塩は、水和物に代表される溶媒和物の形態で存在することもあり、本発明においてはこれらも含まれる。
【0035】
本発明の化合物(1)は、例えば以下の反応式に従って製造できる。
【0036】
[製造法1]
【0037】
【化7】
【0038】
[式中、Ar及びXは前記と同義であり;X1、X2及びX3は各々独立してハロゲン原子を示し;R1はC1−6のアルキル基を示す。]
【0039】
上記製造法は、フェナシル誘導体(2)にエポキシメチレン化剤を反応させてをオキシラン誘導体(3)とし、次いで(3)にイミダゾールもしくは1,2,4−トリアゾール又はそれらの塩を反応させて本発明のアゾール誘導体(1)を得る方法である。
フェナシル誘導体(2)は、例えば、アリールアルコール(4)と2−ハロゲノ−2,2−ジフルオロ酢酸エステル(6)とを反応させて化合物(5)とし、この化合物(5)をハロゲノジフルオロベンゼン(7)と反応させる方法によって得ることができ、また、化合物(7)と2−ハロゲノ−2,2−ジフルオロ酢酸エステル(6’)とを反応させて化合物(8)とした後、アリールアルコール(4)と反応させる方法によっても得ることができる。以下、詳述する。
【0040】
化合物(5)は、アリールアルコール(4)を塩基存在下、2−ハロゲノ−2,2−ジフルオロ酢酸エステル(6)と反応させることにより製造できる。2−ハロゲノ−2,2−ジフルオロ酢酸エステル(6)としては、2−クロロ−2,2−ジフルオロ酢酸エチル、2−ブロモ−2,2−ジフルオロ酢酸エチル等が市販されており、これらを適宜使用することができる。塩基としては、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム、水酸化バリウム、水素化ナトリウム、水素化カリウム、ナトリウムメトキシド、ナトリウムエトキシド、ピリジン、トリエチルアミン、イソプロピルエチルアミン等が使用できるが、水素化ナトリウムが好ましい。反応溶媒としては、メタノール、エタノール、ジエチルエーテル、メタノール−ジエチルエーテル混合溶媒、ジメチルスルホキシド、N,N−ジメチルホルムアミド、1,4−ジオキサン、テトラヒドロフラン等が使用できるが、ジメチルスルホキシドが好ましい。
【0041】
フェナシル誘導体(2)は、塩基存在下、化合物(5)をハロゲノジフルオロベンゼン(7)と反応させることにより製造できる。塩基としては、n−ブチルリチウム、t−ブチルリチウム、リチウムジイソプロピルアミド等が使用できるが、n−ブチルリチウムが好ましい。反応溶媒としては、ジエチルエーテル、テトラヒドロフラン等が使用でき、ジエチルエーテルが好ましい。反応温度は−78〜0℃が好ましい。
【0042】
化合物(8)は、化合物(5)から化合物(2)を製造する上記方法と同様な方法により、化合物(6’)に化合物(7)を反応させることにより得られる。
フェナシル誘導体(2)は、塩基存在下、化合物(8)にアリールアルコール(4)を反応させることにより製造できる。塩基としては、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム、水酸化バリウム、水素化ナトリウム、水素化カリウム、ナトリウムメトキシド、ナトリウムエトキシド、ピリジン、トリエチルアミン、イソプロピルエチルアミン等が使用できるが、炭酸カリウムが好ましい。反応溶媒としては、メタノール、エタノール、ジエチルエーテル、メタノール−ジエチルエーテル混合溶媒、アセトニトリル、ジメチルスルホキシド、N,N−ジメチルホルムアミド、1,4−ジオキサン、テトラヒドロフラン等が使用できるが、アセトニトリルが好ましい。
【0043】
オキシラン誘導体(3)は、フェナシル誘導体(2)に対し、1〜5当量の塩基存在下、1〜2当量のトリメチルスルホキソニウムヨーダイド、トリメチルスルホニウムヨーダイド等のエポキシメチレン化剤を反応させることにより得ることができる。塩基としては、水酸化ナトリウム、水酸化カリウム、水酸化バリウム、ナトリウムメトキシド、ナトリウムエトキシド、炭酸ナトリウム、炭酸カリウム、水素化ナトリウム等が使用でき、水素化ナトリウムが好ましい。溶媒としてはジメチルスルホキシドやテトラヒドロフラン等が好適に使用できる。反応温度は、−100℃〜溶媒の沸点の範囲が好ましく、−40〜50℃がより好ましい。
【0044】
本発明の化合物(1)は、化合物(3)を塩基存在下、イミダゾール、1,2,4−トリアゾール(9)又はそれらのアルカリ金属塩と反応させることにより製造できる。反応溶媒としては、N,N−ジメチルホルムアミド、アセトニトリル、N,N−ジメチルアセトアミド、ジメチルスルホキシド等が使用でき、N,N−ジメチルホルムアミドが好ましい。塩基としては、水酸化ナトリウム、水酸化カリウム、水酸化バリウム、炭酸ナトリウム、炭酸カリウム、tert−ブトキシカリウム等が使用でき、炭酸カリウムが好ましい。反応温度は、0℃〜溶媒の沸点の範囲が好ましく、20〜60℃がより好ましい。
また、化合物(1)は必要に応じ第三級水酸基を塩基存在下アルキル化することができる。
【0045】
[製造法2]
【0046】
【化8】
【0047】
[式中、Xは前記と同義であり;Rは前記説明の通りである。]
【0048】
本発明の化合物(1)においてArが4−ブロモフェニル基である化合物(1)−1は、J.Am.Chem.Soc., 124, 14844−14855(2002)、J.Am.Chem.Soc., 124, 11684−11688(2002)、Organic Letters, 5, 793−796(2003)、Organic Letters, 3, 4295−4298(2001)等に記載の方法に準じ、種々のパラジウム触媒又は銅触媒と配位子化合物とを組み合わせて、ヨウ素化又は炭素−炭素結合もしくは炭素−窒素結合を形成することにより、種々の置換基(R)を導入した化合物(1)−2に変換できる。
【0049】
ヨウ素化は、例えば、化合物(1)−1に配位子存在下にて、ヨウ化銅及びヨウ化ナトリウムを反応させることにより実施できる。配位子としては、トランス−N,N−ジメチル−1,2−シクロヘキサンジアミン、エチレンジアミン、N,N’−ジメチルエチレンジアミン、1,3−ジアミノプロパン、トランス−1,2−ジアミノシクロヘキサン
等が挙げられる。反応溶媒としては、1,4−ジオキサン、N,N−ジメチルホルムアミド、ピリジン、テトラヒドロフラン等が使用でき、1,4−ジオキサンが好ましい。反応温度は室温〜溶媒の沸点範囲が好ましい。
【0050】
パラジウム触媒としては、Pd2(dba)3:トリス(ジベンジリデンアセトン)−ジパラジウム(0)、Pd(PPh)4:テトラキス(トリフェニルホスフィン)パラジウム(0)、PdCl2(PPh3)2 :トランス−ジクロロビス(トリフェニルホスフィン)パラジウム(II)等が挙げられる。
配位子化合物としては、2,2’−ビス(ジフェニルフォスフィノ)−1,1’−ビナフチル(BINAP)、1,1’−2−ビナフトール(BINOL)、2,2’−ビス(オキサゾリル)ビナフチル(BOXAX)、2−ジシクロヘキシルホスフィノ−2’−(N,N−ジメチルアミノ)ビフェニル、トランス−N,N−ジメチル−1,2−シクロヘキサンジアミン、2,2’−ビス(ジ−p−トリル−ホスフィノ)−1,1’−ビナフチル(Tol−BINAP)、1’,2−ビス(ジフェニルホスフィノ)−1−(N,N−ジメチルアミノエチル)フェロセン(BPPFA)、(−)−(2S,4S)−2−ジフェニルホスフィノメチル−4−ジフェニルホスフィノ−1−t−ブトキシカルボニルピロリジン(BPPM)、2,3−ビス(ジフェニルホスフィノ)−ビシクロ[2.2.1]ヘプト−5−エン(NORPHOS)、1,2−ビス(ジフェニルホスフィノ)プロパン(PROPHOS)、O−イソプロピリデン−2,3−ジヒドロキシ−1,4−ビス(ジフェニルホスフィノ)ブタン(DIOP)、1,3−ビス(1−アダマンチル)イミダゾール−2−イリデン(ICy)、1,3−ビス(2,4,6−トリメチルフェニル)イミダゾール−2−イリデン(IMes)等が挙げられる。
【0051】
上記反応後における反応混合物からの目的化合物の単離手段は特に制限されず、例えば溶媒抽出、再結晶、カラムクロマトグラフィー等により行うことができる。また、目的化合物の所望の塩への変換も常法に従って行うことができる。
【0052】
本発明の化合物(1)には、それぞれ不斉炭素原子に基づく鏡像異性体が存在するが、この光学活性体は光学異性体分離用カラムを用いて分離することにより製造することができる。また、光学活性体は光学分割法によっても製造することができる。光学異性体分離用カラム及び光学分割剤については、特開平11−279160号公報、特開平11−240871号公報等に記載がある。
【0053】
本発明の化合物(1)又はその塩の一種又は二種以上を有効成分として含有する医薬組成物は、通常、製剤化に用いられる担体、賦形剤、添加剤を用いて、錠剤、散剤、細粒剤、顆粒剤、カプセル剤、丸剤、液剤、注射剤、坐剤、膣剤、軟膏、貼付剤等に調製され、経口又は非経口投与される。
固形製剤を製造するには、本発明の化合物(1)に賦形剤、更に必要に応じて結合剤、崩壊剤、増量剤、被覆剤、糖衣剤等を加えた後、常法により錠剤、顆粒剤、カプセル剤、坐剤等にすることが好ましい。注射剤を調製する場合は、本発明の化合物(1)を注射用蒸留水等の水性担体にあらかじめ溶解、分散、乳化等して液剤とするか、又は用時溶解用の注射用粉末とすればよい。注射剤の投与方法としては、静脈内投与、動脈内投与、腹腔内投与、皮下投与、静脈点滴等が挙げられる。
【0054】
本発明化合物のヒトに対する投与量は、感染の状態、投与方法によっても異なるが、例えばカンジダ感染症の治療目的で成人患者に投与する場合、経口投与では、約0.01〜100mg/kg/日、好ましくは約0.1〜50mg/kg/日である。さらに好ましくは約1〜20mg/kg/日である。
【0055】
【実施例】
以下に参考例及び実施例を挙げて本発明を更に詳細に説明するが、本発明はこれらに限定されるものではない。
【0056】
[参考例1]2−(4−ブロモフェノキシ)−2,2−ジフルオロ酢酸エチル
p−ブロモフェノール21.4g(0.12mol)をDMSO 150mlに溶解し、室温下、60%NaH 5.45g(0.14mol)を加え15分間攪拌した。室温に戻し、2−クロロ−2,2−ジフルオロ酢酸エチル 21.6g(0.14mol)加え室温で12時間攪拌した。反応終了後、反応液を氷水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=5:1)で精製し、目的物を淡黄色油状物として 25.4g(収率69.4%)得た。
【0057】
[参考例2]2−(4−クロロフェノキシ)−2,2−ジフルオロ酢酸エチル
参考例1と同様な方法により標題化合物を得た(以下、参考例12まで同様。)。
淡黄色油状物:収率49.9%
【0058】
[参考例3]2,2−ジフルオロ−2−(2−フルオロフェノキシ)酢酸エチル
淡黄色油状物:収率46.2%
【0059】
[参考例4]2,2−ジフルオロ−2−(3−フルオロフェノキシ)酢酸エチル
無色油状物:収率32.9%
【0060】
[参考例5]2,2−ジフルオロ−2−(4−フルオロフェノキシ)酢酸エチル
淡黄色油状物:55.5%
【0061】
[参考例6]2,2−ジフルオロ−2−(2−メトキシフェノキシ)酢酸エチル
無色油状物:収率38.8%
【0062】
[参考例7]2,2−ジフルオロ−2−(3−メトキシフェノキシ)酢酸エチル
無色油状物:収率70.0%
【0063】
[参考例8]2,2−ジフルオロ−2−(4−メトキシフェノキシ)酢酸エチル
無色油状物:収率81.6%
【0064】
[参考例9]2−[4−(ベンジルオキシ)フェノキシ]−2,2−ジフルオロ酢酸エチル
淡黄色油状物:収率66.7%
【0065】
[参考例10]2− ([1,1’−ビフェニル] −4−イルオキシ)−2,2−ジフルオロ酢酸エチル
無色結晶:収率50.0%
【0066】
[参考例11]2,2−ジフルオロ−2−(3−ピリジニルオキシ)酢酸エチル
淡褐色油状物:収率27.4%
【0067】
[参考例12] 2−(4−ブロモ−2−フルオロフェノキシ)−2,2−ジフルオロ酢酸エチル
無色油状物:収率50.0%
【0068】
[参考例13]2−(4−ブロモフェノキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
1−ブロモ−2,4−ジフルオロベンゼン 16.6g(0.086mol)をジエチルエーテル 300mlに溶解し、−78℃下、n−ブチルリチウム(2.6Mヘキサン溶液) 36.4ml(0.095mol)を滴下し同温度で1時間攪拌した。次いで、同温度で、2−(4−ブロモフェノキシ)−2,2−ジフルオロ酢酸エチル 25.4g(0.086mol))のジエチルエーテル 30ml溶液を滴下し、−78℃で1時間攪拌後、室温まで温度を上げ2時間攪拌した。反応終了後、飽和塩化アンモニウム水溶液を加え、ジエチルエーテルで抽出し、水洗、飽和塩化ナトリウム水溶液洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=100:1)で精製し、目的物を無色油状物として 25.0g(収率80.0%)得た。
【0069】
[参考例14]2−(4−ブロモフェノキシ)−1−(2,5−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
参考例13と同様な方法により標題化合物を得た(以下、参考例27まで同じ。)
淡黄色油状物:収率69.8%
【0070】
[参考例15]2−(4−クロロフェノキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
淡黄色油状物:収率84.5%
【0071】
[参考例16]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(2−フルオロフェノキシ)−1−エタノン
淡黄色油状物:収率85.8%
【0072】
[参考例17]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(3−フルオロフェノキシ)−1−エタノン
淡黄色油状物:収率81.6%
【0073】
[参考例18]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(4−フルオロフェノキシ)−1−エタノン
淡黄色油状物:収率75.0%
【0074】
[参考例19]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(2−メトキシフェノキシ)−1−エタノン
淡黄色油状物:収率93.5%
【0075】
[参考例20]1−(2,5−ジフルオロフェニル)−2,2−ジフルオロ−2−(4−フルオロフェノキシ)−1−エタノン
淡黄色油状物:収率74.5%
【0076】
[参考例21]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(3−メトキシフェノキシ)−1−エタノン
淡黄色油状物:収率81.2%
【0077】
[参考例22]1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−2−(4−メトキシフェノキシ)−1−エタノン
淡黄色油状物:収率97.7%
【0078】
[参考例23]2−(4−ブロモ−2−フルオロフェノキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
淡黄色結晶:収率97.1%
【0079】
[参考例24]2−([1,1’−ビフェニル]−4−イルオキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
淡黄色結晶:収率55.6%
【0080】
[参考例25]2−[4−(ベンジルオキシ)フェノキシ]−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
無色結晶:収率76.8%
【0081】
[参考例26]2−[4−(tert−ブチル)フェノキシ]−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
淡黄色油状物:収率80.3%
【0082】
[参考例27]1−(2,4−ジフルオロフェノキシ)−2,2−ジフルオロ−2−(3−ピリジニルオキシ)−1−エタノン
淡黄色油状物:収率62.8%
【0083】
[参考例28]2−ブロモ−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
1−ブロモ−2,4−ジフルオロベンゼン 19.3g(0.10mol)をジエチルエーテル 300mlに溶解し、−78℃下、n−ブチルリチウム(2.6Mヘキサン溶液) 40ml(0.10mol)を滴下し同温度で1時間攪拌した。次いで、同温度で、2−ブロモ−2,2 −ジフルオロ酢酸エチル 20.3g(0.10mol)のジエチルエーテル 30ml溶液を滴下し、−78℃で1時間攪拌後、室温まで温度を上げ2時間攪拌した。反応終了後、飽和塩化アンモニウム水溶液を加え、ジエチルエーテルで抽出し、水洗、飽和塩化ナトリウム水溶液洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣を蒸留精製し、bp13
84℃留分を無色油状物として 15.7g(収率57.8%)得た。
【0084】
[参考例29]2−(4−ブロモフェノキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
4−ブロモフェノール 8.65gをアセトニトリル 150mlに溶解し、炭酸カリウム 6.9g(0.05mol)加えて攪拌下、2−ブロモ−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン 13.6g(0.05mol)加え室温で38時間攪拌した。反応終了後、不溶物を濾去して濾液を濃縮した後、残渣に酢酸エチルを加えて溶解し、水洗、飽和塩化ナトリウム水溶液洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。
残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=100:1)で精製し、目的物を無色油状物として 15.7g(収率86.3%)得た。
【0085】
[参考例30]2−(1,3−ベンゼンジオキソール−5−イルオキシ)−1−(2,4−ジフルオロフェニル)−2,2−ジフルオロ−1−エタノン
参考例29と同様な方法により標題化合物を得た(以下、参考例31まで同じ。)
無色油状物:収率58.9%
【0086】
[参考例31]4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−オキソエトキシ]ベンズアルデヒド O−メチルオキシム
黄色油状物:収率88.0%
【0087】
[参考例32]2−[(4−ブロモフェノキシ)(ジフルオロ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン
トリメチルスルホキソニウムヨーダイド 8.58g(0.039mol)をDMSO 50mlに懸濁し、60%NaH 1.56g(0.039mol)加え50℃で0.5時間攪拌した。次いで、2−(4−ブロモフェノキシ)−1−(2,4−ジフルオロ)−1−エタノン 10.9g(0.03mol)のDMSO 15ml溶液を50℃下、滴下し、0.5時間攪拌した。反応終了後、反応物を氷水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=100:1)で精製し、目的物を淡黄色油状物として 7.26g(収率64.2%)得た。
【0088】
[参考例33]2−[(4−ブロモフェノキシ)(ジフルオロ)メチル]−2−(2,5−ジフルオロフェニル)オキシラン
参考例32と同様な方法により標題化合物を得た(以下、参考例47まで同じ)。
淡黄色油状物:収率75.3%
【0089】
[参考例34]2−[(4−クロロフェノキシ)(ジフルオロ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン
淡赤色油状物:収率92.2%
【0090】
[参考例35]2−[ジフルオロ(2−フルオロフェノキシ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン
淡赤色油状物:収率81.4%
【0091】
[参考例36]2−[ジフルオロ(3−フルオロフェノキシ) メチル]−2−(2,4−ジフルオロフェニル)オキシラン
淡褐色油状物:収率81.4%
【0092】
[参考例37]2−[ジフルオロ(4−フルオロフェノキシ) メチル]−2−(2,4−ジフルオロフェニル)オキシラン
淡黄色油状物:収率60.1%
【0093】
[参考例38]2−[ジフルオロ(4−フルオロフェノキシ)メチル]−2−(2,5−ジフルオロフェニル)オキシラン
淡黄色油状物:収率90.0%
【0094】
[参考例39]2−[[2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メトキシ]フェニルメチルエーテル
淡黄色油状物:収率65.0%
【0095】
[参考例40]3−[[2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メトキシ]フェニルメチルエーテル
淡黄色油状物:収率97.5%
【0096】
[参考例41]4−[[2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メトキシ]フェニルメチルエーテル
淡黄色油状物:収率39.7%
【0097】
[参考例42]4−ブロモ−2−フルオロフェニル[2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチルエーテル
淡黄色油状物:収率42.6%
【0098】
[参考例43][1,1’−ビフェニル]−4−イル[2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチルエーテル
淡褐色結晶:収率61.5%
【0099】
[参考例44]2−[[4−(ベンジルオキシ)フェノキシ](ジフルオロ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン
淡黄色油状物:収率64.6%
【0100】
[参考例45]4−(tert−ブチル)フェニル [2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチルエーテル
無色油状物:収率75.3%
【0101】
[参考例46]1,3−ベンゼンジオキソール−5−イル [2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチルエーテル
無色油状物:収率47.4%
【0102】
[参考例47][2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチル 3−ピリジニルエーテル
淡褐色油状物:収率99.0%
【0103】
[実施例1]1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号10) 2−[(4−ブロモフェノキシ)(ジフルオロ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン 8.19g(0.022mol)をDMF 43mlに溶解し、1,2,4−トリアゾール 2.25g(0.033mol)、炭酸カリウム 4.50g(0.033mol)加え室温下、12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(クロロホルム:メタノール=50:1)で精製し、目的物を無色結晶として 4.60g(収率47.5%)得た。
【0104】
融点:110−111℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d, J=14.2Hz), 5.31(1H,d, J=14.2Hz), 5.65(s, 1H), 6.78(m, 1H), 6.90(m, 1H), 6.96(2H,d, J=8.8Hz), 7.44(2H,d, J=8.8Hz), 7.84(m, 1H), 7.88(s, 1H), 8.16(s, 1H).
【0105】
[実施例2]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−フェノキシ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号4)
実施例1と同様な方法により標題化合物を得た(以下、実施例18まで同じ。)。
無色結晶:収率24.0%
融点:114−119℃
1H−NMR(400MHz,CDCl3)δppm:4.95(2H,d,J=14.2Hz),5.32(1H,d,J=14.2Hz),5.6681H,s),6.75−6.81(1H,m),6.87−6.91(1H,m),7.07(2H,d,J=8.30Hz),7.18−7.33(3H,m),7.82−7.86(1H,m),7.86(1H,s),8.16(1H,s).
【0106】
[実施例3]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(2−フルオロフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号5)
無色結晶:収率55.5%
融点:93−94℃
1H−NMR(400MHz,CDCl3)δppm:5.00(1H,d,J=14.2Hz),5.36(1H,d,J=14.2Hz),5.69(1H,s),6.74−6.80(1H,m),6.88−6.93(1H,m),7.07−7.23(4H,m),7.84−7.90(2H,m),8.18(1H,s).
【0107】
[実施例4]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(3−フルオロフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号6)
無色結晶:収率20.9%
融点:113−115℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.6Hz),5.31(1H,d,J=14.6Hz),5.67(1H,s),6.76−6.96(5H,m),7.26−7.31(1H,m),7.82−7.89(2H,m),8.16(1H,s).
【0108】
[実施例5]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−フルオロフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号7)
無色結晶:収率39.9%
融点:97−98℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.2Hz),5.31(1H,d,J=14.2Hz),5.65(1H,s),6.75−7.05(6H,m),7.82−7.88(2H,m),8.16(1H,s).
【0109】
[実施例6]2−(2,5−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−フルオロフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号8)
無色油状物:収率50.0%
1H−NMR(400MHz,CDCl3)δppm:4.94(1H,d,J=14.2Hz),5.34(1H,d,J=14.2Hz),5.73(1H,s),6.97−7.06(6H,m),7.55−7.59(1H,m),7.8(1H,s),8.16(1H,s).
【0110】
[実施例7]1−(4−クロロフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号9)
無色結晶:収率62.2%
融点:98−100℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.2Hz),5.31(1H,d,J=14.2Hz),5.68(1H,s),6.75−6.81(1H,m),6.88−6.93(1H,m),7.01(2H,d,J=9.3Hz),7.28(2H,d,J=9.3Hz),7.82−7.88(2H,m),8.15(1H,s).
【0111】
[実施例8]1−(4−ブロモフェノキシ)−2−(2,5−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号11)無色油状物:収率77.2%
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.7Hz),5.34(1H,d,J=14.7Hz),5.77(1H,s),6.99(4H,m),7.44(2H,m),7.57(1H,m),7.89(1H,s),8.16(1H,s).
【0112】
[実施例9]4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェノール(化合物番号13)後記実施例11で得られる化合物を常法により脱ベンジル化し、目的物を無色結晶として得た。
収率:収率85.4%
融点:127−128℃
1H−NMR(400MHz,CDCl3)δppm:4.97(1H,d,J=14.2Hz),5.28(1H,d,J=14.2Hz),5.46(1H,s),5.54(1H,s),6.74−6.81(3H,m),6.88−6.93(3H,m),7.82−7.89(2H,m),8.18(1H,s).
【0113】
[実施例10]1−[4−(ベンジルオキシ)フェノキシ]−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号14)
無色結晶:収率44.0%
融点:104−105℃
1H−NMR(400MHz,CDCl3)δppm:4.94(1H,d,J=14.2Hz),5.02(2H,s),5.30(1H,d,J=14.2Hz),5.57(1H,s),6.74−6.99(6H,m),7.31−7.42(5H,m),7.82−7.88(2H,m),8.16(1H,s).
【0114】
[実施例11]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(2−メトキシフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号15)
無色結晶:収率55.3%
融点:125−127℃
1H−NMR(400MHz,CDCl3)δppm:
3.80(3H,s),5.01(1H,d,J=14.7Hz),5.37(1H,d,J=14.7Hz),5.43(1H,s),6.75−6.95(4H,m),7.13−7.21(2H,m),7.81−7.87(2H,m),8.19(1H,s).
【0115】
[実施例12]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(3−メトキシフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号16)
無色結晶:収率52.5%
融点:116−119℃
1H−NMR(400MHz,CDCl3)δppm:3.78(3H,s),4.47(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.62(1H,s),6.61−6.92(5H,m),7.21(1H,dd,J=8.3,8.3Hz),7.82−7.88(2H,m),8.16(1H,s).
【0116】
[実施例13]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−メトキシフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号17)
無色結晶:収率10.2%
融点:114−116℃
1H−NMR(400MHz,CDCl3)δppm:3.78(3H,s),4.94(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.58(1H,s),6.75−6.92(4H,m),6.98(2H,d,J=9.3Hz),7.82−7.88(2H,m),8.16(1H,s).
【0117】
[実施例14]1−(4−ブロモ−2−フルオロフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号18)
無色結晶:収率30.6%
融点:97−98℃
1H−NMR(400MHz,CDCl3)δppm:4.97(1H,d,J=14.1Hz),5.34(1H,d,J=14.1Hz),5.73(1H,s),6.74−6.80(1H,m),6.88−6.93(1H,m),7.07−7.11(1H,m),7.23−7.33(2H,m),7.82−7.87(1H,m),7.88(1H,s),8.17(1H,s).
【0118】
[実施例15]4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]ベンズアルデヒド O−メチルオキシム(化合物番号41)
淡黄色油状物:収率5.0%
1H−NMR(400MHz,CDCl3)δppm:3.95(3H,s),4.94(1H,d,J=14.2Hz),5.32(1H,d,J=14.2Hz),5.70(1H,s),6.75−6.92(2H,m),7.07(2H,d,J=8.30Hz),7.53(2H,d,J=8.30Hz),7.82−7.89(1H,m),7.87(1H,s),8.01(1H,s),8.16(1H,s).
【0119】
[実施例16]1−[4−(tert−ブチル)フェノキシ]−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号42)
無色結晶:収率59.6%
融点:168−169℃
1H−NMR(400MHz,CDCl3)δppm:1.29(9H,s),4.95(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.59(1H,s),6.74−6.80(1H,m),6.87−6.91(1H,m),6.98(2H,d,J=8.8Hz),7.32(2H,d,J=8.8Hz),7.82−7.88(2H,m),8.17(1H,s).
【0120】
[実施例17]1−([1,1’−ビフェニル]−4−イルオキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号45)
無色結晶:収率36.5%
融点:135−137℃
1H−NMR(400MHz,CDCl3)δppm:4.98(1H,d,J=14.1Hz),5.35(1H,d,J=14.1Hz),5.63(1H,s),6.77−6.82(1H,m),6.89−6.93(1H,m),7.14(2H,d,J=8.3Hz),7.33−7.36(1H,m),7.41−7.45(2H,m),7.52−7.55(4H,m),7.85−7.91(2H,m),8.18(1H,s).
【0121】
[実施例18]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(3−ピリジニルオキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号47)淡褐色結晶:収率8.0%
融点:110−113℃
1H−NMR(400MHz,CDCl3)δppm:4.95(1H,d,J=14.1Hz),5.34(1H,d,J=14.1Hz),5.75(1H,s),6.77−6.82(1H,m),6.89−6.93(1H,m),7.26−7.31(1H,m),7.43−7.45(1H,m),7.83−7.88(1H,m),7.88(1H,s),8.17(1H,s),8.40(1H,d,J=2.4Hz),8.47−8.48(1H,m).
【0122】
[実施例19]1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−イミダゾール−1−イル)−2−プロパノール(化合物番号2)
2−[(4−ブロモフェノキシ)(ジフルオロ)メチル]−2−(2,4−ジフルオロフェニル)オキシラン 0.19g(0.5mmol)、イミダゾール 0.068g(1.0mmol)の混合物を90℃で1時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(クロロホルム:メタノール=50:1)で精製し、目的物を無色結晶として 0.12g(収率54.5%)得た。
【0123】
融点:146−150℃
1H−NMR(400MHz,CDCl3)δppm:4.66(1H,d,J=14.7Hz),5.01(1H,d,J=14.7Hz),6.46(1H,s),6.74(1H,s),6.84−6.95(2H,m),6.98(2H,d,J=8.8Hz),7.38(1H,s),7.42−7.46(2H,m),7.81−7.87(1H,m).
【0124】
[実施例20]1−(4−クロロフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−イミダゾール−1−イル)−2−プロパノール(化合物番号1)
実施例19と同様な方法により標題化合物を得た。
無色結晶:収率54.1
融点:147−151℃
1H−NMR(400MHz,CDCl3)δppm:4.64(1H,d,J=14.7Hz),5.03(1H,d,J=14.7Hz),6.35(1H,s),6.69(1H,s),6.84−6.94(2H,m),7.03(2H,d,J=8.8Hz),7.29(2H,d,J=8.8Hz),7.38(1H,s),7.87−7.93(1H,m),8.01(1H,brs).
【0125】
[実施例21]1−(4−ブロモフェノキシ)−2−(2,5−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−イミダゾール−1−イル)−2−プロパノール(化合物番号3)
実施例19と同様な方法により標題化合物を得た。
無色結晶:収率52.1%
点:128−130℃
1H−NMR(400MHz,CDCl3)δppm:4.66(1H,d,J=14.6Hz),5.02(1H,d,J=14.6Hz),6.54(1H,brs),6.77(1H,brs),6.99(2H,d,J=8.8Hz),7.05−7.12(2H,m),7.43−7.46(3H,m),7.52−7.59(1H,m).
【0126】
[実施例22]1−(1,3−ベンゼンジオキソール−5−イルオキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号19)
1,3−ベンゼンジオキソール−5−イル [2−(2,4−ジフルオロフェニル)−2−オキシラニル](ジフルオロ)メチル エーテル1.64g(5mmol)、 1,2,4−トリアゾール 0.49g(7.1mmolの混合物を120℃で1時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(クロロホルム:メタノール=50:1)で精製し、目的物を無色結晶として 0.33g(収率35.1%)得た。
【0127】
融点:108−110℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.1Hz),5.30(1H,d,J=14.1Hz),5.58(1H,s),5.97(2H,s),6.51−6.53(1H,m),6.57(1H,d,J=2.0Hz),6.70(1H,d,J=8.3Hz),6.75−6.81(1H,m),6.87−6.91(1H,m),7.81−7.85(1H,m),7.86(1H,s),8.16(1H,s).
【0128】
[実施例23]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ1−[4−(4−フェニルピペラジノ)フェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号31)
1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.223g(0.5mmol)、1−フェニルピペラジン 0.086ml(0.56mmol)、Pd2(dba)3 (Pd2(dba)3:トリス(ジベンジリデンアセトン)−ジパラジウム(0)) 0.0046g(0.005mmol)、BINAP(BINAP:2,2’−ビス(ジフェニルホスフィノ)−1,1’−ビナフチル) 0.0094g(0.015mmol)、ナトリウムt−ブトキシド 0.135g(1.4mmol)、トルエン 2.5mlの混合物を80℃で16時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=1:1)で精製し、目的物を無色結晶として 0.085g(収率32.0%)得た。
【0129】
融点:97−105℃
1H−NMR(400MHz,CDCl3)δppm:3.28−3.33 (8H, m), 4.95 (1H, d, J=14.7 Hz), 5.32 (1H, d, J=14.7 Hz), 5.54 (1H, s), 6.75−6.81 (1H, m), 6.88−6.91 (4H, m),6.97−6.99 (4H, m), 7.26−7.31 (2H, m), 7.82−7.87 (1H, m), 7.87 (1H, s),8.16 (1H, s).
【0130】
[実施例24]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ピペリジノフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号27)
実施例23と同様な方法により標題化合物を得た(以下、実施例33まで同じ。)。
無色結晶:収率50.0%
融点:137−142℃
1H−NMR(400MHz,CDCl3)δppm:1.52−1.58 (2H, m), 1.66−1.71 (4H, m), 3.09 (4H, t, J=5.7 Hz), 4.94 (1H, d, J=14.6 Hz), 5.31 (1H, d, J=14.6 Hz), 5.50 (1H, s), 6.99−6.73 (6H, m),7.81−7.87 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
【0131】
[実施例25]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−モルフォリノフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号28)
無色結晶:収率27.0%
融点:115−119℃
1H−NMR(400MHz,CDCl3)δppm:3.09−3.11(4H,m),3.83−3.85(4H,m),4.94(1H,d,J=14.2Hz),5.30(1H,d,J=14.2Hz),5.55(1H,s),6.75−6.98(2H,m),6.82(2H,d,J=8.8Hz),6.97(2H,d,J=8.8Hz),7.81−7.85(1H,m),7.87(1H,s),8.16(1H,s).
【0132】
[実施例26]4−[4−[2−ヒドロキシ−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニルテトラヒドロ−1(2H)−ピラジン]カルボン酸 tert−ブチル(化合物番号30)
無色結晶:収率64.0%
融点:130−134℃
1H−NMR(400MHz,CDCl3)δppm:1.47(9H,s),3.05−3.08(4H,m),3.54−3.57(4H,m),4.94(1H,d,J=14.7Hz),5.31(1H,d,J=14.7Hz),5.56(1H,s),6.74−6.91(2H,m),6.84(2H,d,J=7.3Hz),6.96(2H,de,J=7.3Hz),7.81−7.85(1H,m),7.87(1H,s),8.16(1H,s).
【0133】
[実施例27]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(4−フルオロフェニル)ピペラジノフェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号32)
無色結晶:収率17.9%
融点:97−98℃
1H−NMR(400MHz,CDCl3)δppm:3.23−3.30(8H,m),4.95(1H,d,J=14.2Hz),5.32(1H,d,J=14.2Hz),5.57(1H,s),6.75−7.01(10H,m),7.82−7.88(2H,m),8.17(1H,s).
【0134】
[実施例28]2−(2,5−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(4−フルオロフェニル)ピペラジノフェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号33)
無色結晶:収率48.3%
融点:156−158℃
1H−NMR(400MHz,CDCl3)δppm:3.23−3.30(8H,m),4.95(1H,d,J=14.2Hz),5.35(1H,d,J=14.2Hz),5.62(1H,s),6.88−7.01(10H,m),7.55−7.60(1H,m),7.89(1H,s),8.16(1H,s).
【0135】
[実施例29]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(4−ニトロフェニル)ピペラジノフェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号34)
黄色結晶:収率25.9%
融点:150−154℃
1H−NMR(400MHz,CDCl3)δppm:3.29−3.31(4H,m),3.56−3.59(4H,m),4.96(1H,d,J=14.7Hz),5.31(1H,d,J=14.7Hz),5.58(1H,s),6.75−6.81(1H,m),6.85−6.92(5H,m),6.98−7.01(2H,m),7.82−7.88(2H,m),8.13−8.17(3H,m).
【0136】
[実施例30]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(3−メトキシフェニル)ピペラジノフェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号35)
無色結晶:収率6.3%
融点:134−137℃
1H−NMR(400MHz,CDCl3)δppm:3.26−3.33(8H,m),3.80(3H,s),4.95(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.55(1H,s),6.44−6.60(3H,m),6.75−7.00(6H,m),7.20(1H,dd,J=8.3,8.3Hz),7.82−7.88(2H,m),8.16(1H,s).
【0137】
[実施例31]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(3−クロロフェニル)ピペラジノフェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号36)
無色結晶:収率7.8%
融点:123−126℃
1H−NMR(400MHz,CDCl3)δppm:3.26−3.34(8H,m),4.95(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.56(1H,s),6.75−7.00(9H,m),7.19(1H,dd,J=8.3,8.3Hz),7.86(2H,m),8.16(1H,s).
【0138】
[実施例32]4−[4−(2−ヒドロキシ−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ)フェニル]−1−(4−メトキシフェニル)テトラヒドロ−2(1H)−ピラジノン(化合物番号37)
無色結晶:収率31.0%
融点:148−152℃
1H−NMR(400MHz,CDCl3)δppm:3.55−3.57(2H,m),3.79−3.81(2H,m),3.81(3H,s),4.00(2H,bs),4.94(1H,d,J=14.2Hz),5.30(1H,d,J=14.2Hz),5.61(1H,s),6.76−6.92(2H,m),6.83(2H,d,J=8.8Hz),6.93(2H,d,J=8.8Hz),7.02(2H,d,J=8.8Hz),7.21(2H,d,J=8.8Hz),7.84−7.85(1H,m),7.87(1H,s),8.16(1H,s).
【0139】
[実施例33]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ピペラジノフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号29)
実施例26で得られた化合物をトリフルオロ酢酸を用いて常法により脱ブチル化し、目的物を淡黄色油状物として得た。
収率:収率89.0%
1H−NMR(400MHz,CDCl3)δppm:3.00−0.09(8H,m),4.94(1H,d,J=14.2Hz),5.30(1H,d,J=14.2Hz),6.74−6.91(2H,m),6.83(2H,d,J=9.3Hz),6.95(2H,d,J=9.3Hz),7.80−7.84(1H,m),7.86(1H,s),8.15(1H,s).
【0140】
[実施例34]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(3−メトキシプロピル)アミノ]フェニル−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号20)
1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.224g(0.5mmol)、3−メトキシプロピルアミン 0.08ml(0.78mmol)、ヨウ化銅 0.0057g(0.03mmol)、N,N−ジエチル−2−ヒドロキシベンザミド 0.0195g(0.1mmol)、リン酸三カリウム 0.212g(1.0mmol)、1,4−ジオキサン 0.5mlの混合物を90℃で12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=2:1)で精製し、目的物を無色結晶として 0.024g(収率10.0%)得た。
【0141】
融点:104−106℃
1H−NMR(400MHz,CDCl3)δppm:1.86 (2H, quint, J=5.8 Hz), 3.17 (2H, t, J=6.3Hz), 3.34 (3H, s), 3.49 (2H, t, J=6.3 Hz), 4.93 (1H, d, J=14.1 Hz), 5.30(1H, d, J=14.1 Hz), 5.47 (1H, s), 6.49−6.51 (2H, m), 6.73−6.79 (1H, m), 6.84−6.90 (3H, m), 7.80−7.85 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
【0142】
[実施例35]メチル (E)−3−4−[2−(2,4−ジフオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニル−2−プロペノエート(化合物番号40)
1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.446g(1.0mmol)、アクリル酸メチル 0.1ml(1.1mmol)、Pd2(dba)3 0.0135g(0.015mmol)、[(tBu)3Ph]BF4 ([(tBu)3Ph]BF4:トリ−t−ブチルフォスフォニウムテトラフルオロボレート) 0.0088g(0.03mmol)、ジシクロヘキシルメチルアミン 0.24ml(1.1mmol)、1,4−ジオキサン1.0mlの混合物を120℃で12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=2:1)で精製し、目的物を無色結晶として 0.209g(収率46.0%)得た。
【0143】
融点:149−151℃
1H−NMR(400MHz,CDCl3)δppm:3.80 (3H, s), 4.95 (1H, d, J=14.6 Hz), 5.32 (1H, d, J=14.6 Hz), 5.67 (1H, s), 6.37 (1H, d, J=16.1 Hz), 6.75−6.81 (1H, m), 6.88−6.93 (1H, m), 7.09 (2H, d, J=8.3 Hz), 7.48 (2H, d, J=8.3 Hz), 7.64 (1H, d, J=16.1 Hz), 7.82−7.87 (1H, m), 7.88 (1H, s), 8.16 (1H, s).
【0144】
[実施例36]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[(4’−メトキシ[1,1’−ビフェニル]−4−イル)オキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号46)
1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ3−(H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.224g(0.5mmol)、4−メトキシフェニルボロニックアシド 0.320g(0.65mmol)、Pd(PPh)4 (Pd(PPh)4:テトラキス(トリフェニルホスフィン)パラジウム(0)) 0.0345g(0.03mmol)、2M炭酸ナトリウム 4.5ml、トルエン 7ml、エタノール 0.5mlの混合物を100℃で12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=1:1)で精製し、目的物を無色結晶として 0.192g(収率81.0%)得た。
【0145】
融点:150−152℃
1H−NMR(400MHz,CDCl3)δppm:3.84 (3H, s), 4.97 (1H, d, J=14.1 Hz), 5.34 (1H, d, J=14.1 Hz), 5.61 (1H, s), 6.76−6.82 (1H, m), 6.88−6.93 (1H, m), 6.95−6.97 (1H, m), 7.11 (2H, d, J=8.8 Hz), 7.45−7.49 (4H, m), 7.84−7.89 (1H, m), 7.89 (1H, s), 8.17 (1H, s).
【0146】
[実施例37]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ1−(4−ヨードフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号12)
1−(4−ブロモフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.446g(1mmol)、ヨウ化銅 0.00952g(0.05mmol)、トランス−N,N−ジメチル−1,2−シクロヘキサンジアミン 0.0142g(0.1mmol)、ヨウ化ナトリウム 0.30g(2mmol)、1,4−ジオキサン2mlの混合物を110℃で24時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=1:1)で精製し、目的物を無色結晶として 0.40g(収率81.0%)得た。
【0147】
融点:130−132℃
1H−NMR(400MHz,CDCl3)δppm:8.15(1H,s),7.87(1H,s),7.85−7.81(1H,m),7.62(2H,d,J=8.8Hz),6.96−6.75(2H,m),6.83(2H,d,J=8.8Hz),5.66(1H,s),5.30(1H,d,J=14.2Hz),4.92(1H,d,J=14.2Hz).
【0148】
[実施例38]1−4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニル−2−ピロリジノン(化合物番号25)
2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ヨードフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.173g(0.35mmol)、2−ピロリジノン 0.036g(0.42mmol)、ヨウ化銅 0.0034g(0.0175mmol)、リン酸三カリウム 0.15g(0.7mmol)、トランス−N,N−ジメチル−1,2−シクロヘキサンジアミン 0.005g(0.035mmol)、1,4−ジオキサン 0.35mlの混合物を110℃で48時間攪拌した。
反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=1:1)で精製し、目的物を無色結晶として 0.040g(収率25.0%)得た。
【0149】
融点:106−109℃
1H−NMR(400MHz,CDCl3)δppm:2.14(2H,m),2.58−2.62(2H,m),3.81−3.84(2H,m),4.95(1H,d,J=14.7Hz),5.32(1H,d,J=14.7Hz),5.63(1H,s),6.75−6.91(2H,m),7.06(2H,d,J=8.8Hz),7.57(2H,d,J=9.3Hz),7.83−7.85(1H,m),7.87(1H,s),8.16(1H,s).
【0150】
[実施例39]N−4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ −3−(1H−1,2,4−トリアゾール−1−イル) プロポキシ]フェニルカルバミン酸ベンジル(化合物番号21)
実施例38と同様にして標題化合物を得た(以下、実施例43まで同じ。)。無色結晶:収率62.0%
融点:139−142℃
1H−NMR(400MHz,CDCl3)δppm:4.93(1H,d,J=14.2Hz),5.18(2H,s),5.30(1H,d,J=14.2Hz),5.61(1H,s),6.71(1H,bs),6.74−6.91(2H,m),7.00(2H,d,J=8.8Hz),7.32−7.38(8H,m),7.80−7.84(1H,m),7.87(1H,s),8.16(1H,s).
【0151】
[実施例40]N−4−[1,1−ジフルオロ−2−(2,4−ジフルオロフェニル)−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニル−4−メチルベンザミド(化合物番号22)
無色結晶:収率46.0%
融点:111−116℃
1H−NMR(400MHz,CDCl3)δppm:3.13(3H,s),4.92(1H,d,J=14.7Hz),5.37(1H,d,J=14.7Hz),6.80−6.90(2H,m),7.09(2H,d,J=8.8Hz),7.27(2H,d,J=7.8Hz),7.62(2H,d,J=8.8Hz),7.70−7.81(1H,m),7.79(2H,d,J=7.8Hz),8.23(1H,s),8.79(1H,s).
【0152】
[実施例41]N−4−[1,1−ジフルオロ−2−ヒドロキシ−2−(2,4−ジフルオロフェニル)−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニル−4−メチルベンゼンスルホンアミド(化合物番号23)
無色結晶:収率17.0%
融点:174−176℃
1H−NMR(400MHz,CDCl3)δppm:2.37(3H,s),4.89(1H,d,J=14.2Hz),5.30(1H,d,J=14.2Hz),6.78−6.95(2H,m),6.94(2H,d,J=8.3Hz),7.02(2H,d,J=8.3Hz),7.21(2H,d,J=7.8Hz),7.60(2H,d,J=7.8Hz),7.77−7.85(1H,m),7.85(1H,s),8.17(1H,s).
【0153】
[実施例42]2−[4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル) プロポキシ]フェニル]−4−(4−メトキシフェニル)−2,4−ジヒドロ−3H−1,2,4−トリアゾール−3−オン(化合物番号24)
反応溶媒をN,N−ジメチルホルムアミド、及び反応時間を16時間に変える以外は実施例38と同様にして標題化合物を無色結晶として得た。
【0154】
収率:収率29.0%
融点:137−140℃
1H−NMR(400MHz,CDCl3)δppm:3.84(3H,s),4.95(1H,d,J=14.2Hz),5.34(1H,d,J=14.2Hz),6.76−6.92(2H,m),7.00(2H,d,J=9.3Hz),7.15(2H,d,J=8.8Hz),7.44(2H,d,J=8.8Hz),7.75(1H,s),7.83−7.87(1H,m),7.88(1H,s),7.99(2H,d,J=9.3Hz),8.17(1H,s).
【0155】
[実施例43]3−4−[2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1H−1,2,4−トリアゾール−1−イル)プロポキシ]フェニル−1,3−オキサゾラン−2−オン(化合物番号26)
無色結晶:収率58.0%
融点:85−92℃
1H−NMR(400MHz,CDCl3)δppm:4.01−4.03(2H,m),4.46−4.49(2H,m),4.94(1H,d,J=14.2Hz),5.32(1H,d,J=14.2Hz),5.67(1H,s),6.76−6.91(2H,m),7.08(1H,d,J=8.8z),7.49(2H,d,J=8.8z),7.84−7.87(1H,m),7.87(1H,s),8.17(1H,s).
【0156】
[実施例44]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(1H−ピラゾール−1−イル)フェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号38)
2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ヨードフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.493g(1.0mmol)、ピラゾール 0.075g(1.1mmol)、ヨウ化銅 0.019g(0.1mmol)、リン酸三カリウム 0.425g(2.0mmol)、トランス−N,N−ジメチル−1,2−シクロヘキサンジアミン 0.028g(0.2mmol)、1,4−ジオキサン 1.0mlの混合物を120℃で12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=2:1)で精製し、目的物を無色結晶として 0.342g(収率78.0%)得た。
【0157】
融点:142−143℃
1H−NMR(400MHz,CDCl3)δppm:4.96 (1H, d, J=14.1), 5.33 (1H, d, J=14.1), 5.65 (1H, s), 6.46 (1H, t, J=2.0), 6.76−6.82 (1H, m), 6.88−6.93 (1H, m), 7.16 (2H, d, J=8.8), 7.63−7.66 (2H, m), 7.66 (1H, s), 7.71 (1H, d, J=2.0),7.83−7.89 (3H, m), 8.18 (1H, s).
【0158】
[実施例45]2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−[4−(1H −イミダゾール−1−イル)フェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号39)
実施例44と同様にして標題化合物を得た。
無色結晶:収率32.0%
融点:139−141℃
1H−NMR(400MHz,CDCl3)δppm:4.97 (1H, d, J=14.1Hz), 5.33 (1H, d, J=14.1 Hz), 5.83 (1H, s), 6.77−6.83 (1H, m), 6.89−6.94 (1H, m), 7.18−7.23 (3H, m), 7.26−7.37 (2H, m), 7.80 (1H, s), 7.84−7.90 (3H, m), 8.17 (1H, s).
【0159】
[実施例46]1−(4−アリルフェノキシ)−2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号43)
2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ヨードフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.247g(0.5mmol)、アリルトリブチルチン 0.33ml(1.0mmol)、Pd(PPh)4 (Pd(PPh)4:テトラキス(トリフェニルホスフィン)パラジウム(0))0.058g(0.05mmol)、トルエン 10mlの混合物を120℃で12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=2:1)で精製し、目的物を無色結晶として 0.099g(収率49.0%)得た。
【0160】
融点:124−126℃
1H−NMR(400MHz,CDCl3)δppm:3.35 (1H, d, J=6.4Hz 4.95 (1H, d, J=14.1Hz 5.03 (1H, m), 5.07 (1H, s), 5.32 (1H, d, J=14.1Hz), 5.58 (1H, s), 5.87−5.97
(1H, m), 6.74−6.80 (1H, m), 6.87−6.91 (1H, m), 6.98 (2H, d, J=8.8Hz),7.13 (2H, d, J=8.8Hz), 7.82−7.86 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
【0161】
[実施例47]2−(2,4−ジフルオロフェニル)−1,1− ジフルオロ−1−[4−(2−フェニルエチニル)フェノキシ]−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール(化合物番号44)
2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(4−ヨードフェノキシ)−3−(1H−1,2,4−トリアゾール−1−イル)−2−プロパノール 0.247g(0.5mmol)、フェニルアセチレン 0.33ml(1.0mmol)、PdCl2(PPh3)2 (PdCl2(PPh3)2 :トランス−ジクロロビス(トリフェニルホスフィン)パラジウム(II))0.007g(0.01mmol)、ヨウ化銅 0.0041g(0.02mmol)、トリエチルアミン 0.1ml、DMF 2mlの混合物を室温下、12時間攪拌した。反応終了後、反応液を水中にあけ、酢酸エチルで抽出し、水洗、飽和塩化ナトリウム水溶液で洗浄後、硫酸水素ナトリウムで乾燥し溶媒留去した。残渣をシリカゲルクロマトグラフィー(酢酸エチル:ヘキサン=2:1)で精製し、目的物を無色結晶として 0.178g(収率72.0%)得た。
【0162】
融点:115−117℃
1H−NMR(400MHz,CDCl3)δppm:5.96 (1H, d, J=14.1Hz 5.33 (1H, d, J=14.1Hz 5.64 (1H, s), 6.76−6.82 (1H, m), 6.88−6.93 (1H, m), 7.04 (2H, d, J=8.8Hz),7.35 (2H, m), 7.47−7.52 (4H, m), 7.83−7.89 (1H, m), 7.92 (1H, s), 8.24 (1H, s).
【0163】
[試験例1]<抗真菌活性測定>
NCCLS protocols M37−A2及びM38−Aに従い、以下の手順でMICを測定した。
被検化合物溶液:被検化合物をdimethyl sulfoxide (DMSO)に溶解して最高6.4
mg/mLとし、DMSOで希釈して2倍希釈系列を作製した。
試験菌株:Candida albicans ATCC 90028、C. albicans No. 10674 (fluconazole耐性株)、C. albicans No. 89574(同)、C. krusei ATCC 6258、Aspergillus flavus IFM 41935、A. fumigatus IFM 40808、Trichophyton mentagrophytes IFM 40769及びT. rubrum IFO 6204を用いた。
抗真菌活性測定:試験培地としてRPMI1640を用い、被検化合物のDMSO溶液を試験培地で50倍希釈して96穴丸底マイクロプレートの所定ウエルに100μLずつ分注した。次にCandida属真菌を滅菌生理食塩水に懸濁して、濁度をMcFarland 0.5とした後、試験培地で1000倍希釈して接種菌液とし、またAspergillus属真菌及びTrichophyton属真菌を試験培地にて6.0 × 104 conidia/mL及び2.0 × 105 conidia/mLに調製して接種菌液とした。これらの接種菌液100μLを96穴丸底マイクロプレートの所定ウエルに分注し、Candida属真菌及びAspergillus属真菌は35℃で48時間、Trichophyton属真菌は27℃で72時間培養した。培養終了後、Candida属真菌については吸光度(600 nm)を測定し、薬剤無添加対照と比較して80%以上菌の生育を抑制した最小薬剤濃度をMIC (μg/ml)とした。また、Aspergillus属真菌及びTrichophyton属真菌については目視で判定し、薬剤無添加対照と比較して50%以上菌の生育を抑制した最小薬剤濃度をMICとした。
【0164】
表4中の略称は以下の真菌及び化合物を意味する。
C.alb:Candida albicans ATCC 90028
C.kru:Candida C.krusei ATCC 6258
A.fla:Aspergillus flavus IFM 41935
A.fum:A. fumigatus IFM 40808
T.men:Trichophyton mentagrophytes IFM 40769T.rub:Trichophyton rubrum IFO 6204
FLCZ:フルコナゾール
【0165】
【表4】
【0166】
【表5】
【0167】
表4から明らかなように、本発明の化合物(1)は、深在性真菌症及び表在性真菌症の原因菌に対し優れた抗菌活性を示し、特に、アスペルギルスに対しては、対照薬であるフルコナゾールより特に優れた抗菌活性を示した。また、表5から明らかなように、本発明の化合物(1)は、フルコナゾール耐性菌に対しても優れた抗菌活性を示した。
【0168】
【発明の効果】
本発明のアゾール誘導体又はその塩は、深在性真菌症及び表在性真菌症の原因菌に対して優れた抗菌活性を示し、これを有効成分とする抗真菌剤はヒトを含む哺乳類動物の真菌による感染症予防及び治療に有用である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an azole derivative or a salt thereof having excellent antifungal activity and high safety, a production intermediate thereof, and a medicament containing the same as an active ingredient.
[0002]
[Prior art]
Mycosis includes superficial mycosis typified by various tinea, tinea, psoriasis, cutaneous candidiasis, and fungal meningitis, fungal respiratory infections, mycemia, uromycosis, etc. There is deep mycosis represented. Among these, deep-seated mycosis such as candidiasis and aspergillosis has tended to increase particularly in recent years due to the frequent use of cancer chemotherapeutic agents and immunosuppressive agents, and a decrease in in vivo immunity due to HIV infection and the like. A drug effective against bacteria is desired.
[0003]
However, as a drug effective against Aspergillus and Candida, amphotericin B and azole compounds such as fluconazole and itraconazole are conventionally known, but they are still scarce. In addition, these drugs have problems in safety or antifungal activity, and antifungal agents effective against Aspergillus and Candida have been desired. Currently, more effective azole compounds are being developed, for example, 2,2-difluoro-2-alkylthiomethyl group, 2,2-difluoro-2-alkylsulfinylmethyl group, or 2,2-difluoro-2. Triazole derivatives having an alkylsulfonylmethyl group are known (see Patent Documents 1 to 3), but are not always satisfactory.
[0004]
[Patent Document 1]
JP-A-9-227531
[Patent Document 2]
JP-A-11-240871
[Patent Document 3]
JP-A-11-279160
[0005]
[Problems to be solved by the invention]
Therefore, an object of the present invention is to provide a novel azole derivative which is highly safe and has an effective antifungal activity against deep mycosis and superficial mycosis.
[0006]
[Means for Solving the Problems]
Under such circumstances, the present inventors have synthesized a large number of azole derivatives or salts thereof, and have conducted intensive studies on their antifungal activity. As a result, the present inventors have found that a novel azole derivative represented by the following general formula (1) or a salt thereof Shows excellent antibacterial activity against causative bacteria of deep mycosis and superficial mycosis, and also exhibits antibacterial activity against fluconazole-resistant bacteria, and has low toxicity, and inhibits CYP (cytochrome P450). The inventors have also found that the safety of the action is weak, and completed the present invention.
[0007]
That is, the present invention provides the following general formula (1):
[0008]
Embedded image
[0009]
[Wherein, X represents N or CH; Ar represents a phenyl group which may have a substituent or an aromatic heterocyclic group which may have a substituent. The present invention provides an azole derivative represented by the formula (I) or a salt thereof, a production intermediate thereof, and a method for producing these compounds.
[0010]
The present invention also provides a medicine comprising the azole derivative represented by the above general formula (1) or a salt thereof as an active ingredient.
[0011]
BEST MODE FOR CARRYING OUT THE INVENTION
The azole derivative of the present invention is represented by the general formula (1). In the formula, the substituent (R) which the phenyl group represented by Ar may have is a halogen atom, a halogeno C1-6Alkyl group, C1-6Alkyl group, C1-6C, which may have an alkoxy group, a nitro group, a hydroxy group, a carboxy group, a cyano group, or a substituent2-6An alkenyl group, which may have a substituent2-6Alkynyl group, phenyl group which may have a substituent, C7-26Aralkyloxy group, C1-6Alkylenedioxy group, amino group which may have a substituent, carbamoyl group which may have a substituent, sulfonylamino group which may have a substituent, 4- to 7-membered alicyclic ring which may have a substituent Formula heterocyclic group, aromatic heterocyclic group which may have a substituent, C1-6And alkoxyimino groups.
[0012]
Examples of the halogen atom include F, Cl, Br, I and the like.
[0013]
Halogeno C1-6Alkyl group, C1-6C in alkyl group, etc.1-6As the alkyl, C1-6Linear or branched alkyl. C1-6Examples of the straight chain alkyl include methyl, ethyl, n-propyl, n-butyl and the like, and examples of the branched chain alkyl include isopropyl, isobutyl, sec-butyl, tert-butyl and the like. Halogeno C1-6Examples of the alkyl group include a fluoromethyl group, a chloromethyl group, a bromomethyl group, a fluoroethyl group, a chloroethyl group, and a bromoethyl group.
[0014]
C1-6Alkoxy group, C1-6C in an alkoxyimino group, etc.1-6Alkoxy includes C1-6And specific examples thereof include methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy and the like. C1-6Specific examples of the alkoxyimino group include an N-methoxyimino group and an N-ethoxyimino group.
[0015]
Examples of the phenyl group which may have a substituent include an unsubstituted phenyl group and the above-mentioned C1-6Alkyl group, C1-6Examples include a phenyl group substituted with an alkoxy group, and specific examples include a methylphenyl group, an ethylphenyl group, a methoxyphenyl group, and an ethoxyphenyl group.
[0016]
C which may have a substituent2-6As the alkenyl group, an unsubstituted C2-6In addition to the alkenyl group, the above C1-6Alkyl group, C1-6Alkoxy group, C1-6C substituted with an alkoxycarbonyl group, etc.2-6An alkenyl group is exemplified. C1-6Examples of the alkoxycarbonyl group include the above-mentioned C1-6It has an alkyl group, and specific examples include a methoxycarbonyl group and an ethoxycarbonyl group. The C2-6Specific examples of the alkenyl group include a vinyl group, a 2-propenyl group, a 2-methoxycarbonylethenyl group, and a 2-ethoxycarbonylethenyl group.
[0017]
C which may have a substituent2-6Alkynyl groups include unsubstituted C2-6In addition to the alkynyl group, the above C1-6Alkyl group, C1-6Alkoxy group, C6-20C substituted with an aryl group, etc.2-6An alkynyl group is exemplified. C6-20Specific examples of the aryl group include a phenyl group and a naphthyl group. The C2-6As the alkynyl group, a 2-phenylethynyl group is preferable.
[0018]
C7-26C of aralkyloxy group7-26Aralkyl is the above C1-6Alkyl and the above C6-20An aryl group;7-26Specific examples of the aralkyloxy group include a benzyloxy group and a phenethyloxy group.
[0019]
C1-6C of the alkylenedioxy group1-6Alkylene includes methylene and ethylene;1-6As the alkylenedioxy group, a methylenedioxy group is preferable.
[0020]
Examples of the amino group which may have a substituent include the above-mentioned C1-6And an amino group substituted with an alkyl group further substituted with an alkoxy group. Specific examples include a methoxymethylamino group, a 2-methoxyethylamino group, a 3-methoxypropylamino group, an ethoxymethylamino group, a 2-ethoxyethylamino group, and a 3-methoxypropylamino. Amino groups are preferred.
[0021]
The carbamoyl group which may have a substituent includes, in addition to the unsubstituted carbamoyl group,1-6Alkyl group, C7-26Aralkyloxy group, C1-6Examples include a carbamoyl group substituted with a phenyl group and the like further substituted with an alkyl group, and specific examples include a benzyloxycarbamoyl group and a 4-methylphenylcarbamoyl group.
[0022]
Examples of the substituent on the sulfonylamino group that may have a substituent include those similar to the substituent that the carbamoyl group may have, and a methylphenyl group and an ethylphenyl group are preferable, and a methylphenyl group is preferable. More preferred. As the sulfonylamino group, a methylphenylsulfonylamino group is preferable.
[0023]
Examples of the alicyclic heterocyclic group in the 4- to 7-membered alicyclic heterocyclic group which may have a substituent include a pyrrolidinyl group, an imidazolidinyl group, a piperidyl group, a piperazinyl group, a pyrazolidinyl group, a morpholinyl group, a thiomorpholinyl group, and an oxazolidinyl group. And the like. As a substituent on the alicyclic heterocyclic group, an oxo group, the following C1-6An alkoxycarbonyl group, a phenyl group which may have a substituent, a halogen atom, a halogeno C1-6Alkyl group, C1-6Alkyl group, C1-6An alkoxy group, a hydroxy group, an amino group, a cyano group, a carbamoyl group, a carboxyl group, a nitro group, a sulfonamide group, and the like; an oxo group;1-6Alkoxycarbonyl groups and phenyl groups which may have the above substituents are preferred. The number of substituents is preferably 1 to 3. C1-6As the alkoxycarbonyl group, a methoxycarbonyl group, an ethoxycarbonyl group and a tert-butoxycarbonyl group are preferred, and a tert-butoxycarbonyl group is more preferred. Examples of the substituent on the phenyl group include the above C1-6Alkyl group, C1-6An alkoxy group, a halogen atom and a nitro group are preferred, and a methoxy group, a fluorine atom, a chlorine atom and a nitro group are more preferred. The number of substituents on the phenyl group is preferably 1 to 5, and more preferably 1 to 3.
[0024]
Examples of the aromatic heterocyclic group which may have a substituent include a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, an isothiazolyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a triazolyl group, and a pyridyl group. , Pyridazinyl group, pyrazinyl group, pyrimidinyl group and the like, and a pyrazolyl group, imidazolyl group and triazolyl group are preferred. Examples of the substituent on the aromatic heterocyclic group include the same substituents that the alicyclic heterocyclic group may have, and the triazolyl group is preferably substituted with an oxo group.
[0025]
The number of substituents on the phenyl group which may have a substituent represented by Ar is preferably 1 to 3.
[0026]
The aromatic heterocyclic group of the aromatic heterocyclic group which may have a substituent represented by Ar in the general formula (1) includes a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, an isothiazolyl group, an imidazolyl group. , Oxazolyl, thiazolyl, triazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, benzopyrrolyl, benzofuranyl, benzothienyl, benzopyrazolyl, benzisoxazolyl, benzoisothiazolyl, benzimidazolyl Group, benzoxazolyl group, benzothiazolyl group, quinolyl group, isoquinolyl group, cinnolinyl group, phthalazinyl group, quinazolinyl group, quinoxalinyl group and the like. Examples of the substituent on the aromatic heterocyclic group include those similar to the substituent on the phenyl group which may have a substituent represented by Ar, and the number of the substituents is preferably 1 to 3.
[0027]
Ar represented by the general formula (1) is preferably a phenyl group which may have a substituent or an unsubstituted pyridyl group, more preferably a phenyl group which may have a substituent, and is a compound number shown in Table 1 below. Groups corresponding to 1-46 are particularly preferred.
[0028]
In the azole derivative represented by the general formula (1), the position of two fluorine atoms substituted with a phenyl group bonded to the same carbon atom as a carbon atom bonded to a tertiary hydroxyl group is 2,4- or 2, It is preferably 5-, and more preferably 2,4-.
[0029]
Preferred specific examples of the compound of the present invention represented by the general formula (1) are shown below.
[0030]
[Table 1]
[0031]
[Table 2]
[0032]
[Table 3]
[0033]
The salt of the compound (1) of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt, but acid addition salts such as hydrochloride, nitrate, hydrobromide, p-toluenesulfonate, Examples include methanesulfonate, fumarate, succinate, lactate and the like.
[0034]
The compound (1) of the present invention or a salt thereof has stereoisomers based on an asymmetric carbon atom, and the present invention includes any of these isomers and a mixture of isomers such as a racemate. Further, the azole derivative or a salt thereof may exist in the form of a solvate represented by a hydrate, and these are included in the present invention.
[0035]
The compound (1) of the present invention can be produced, for example, according to the following reaction formula.
[0036]
[Production method 1]
[0037]
Embedded image
[0038]
[Wherein, Ar and X are as defined above;1, X2And X3Each independently represents a halogen atom;1Is C1-6Represents an alkyl group. ]
[0039]
The above production method comprises reacting a phenacyl derivative (2) with an epoxymethylene reagent to form an oxirane derivative (3), and then reacting (3) with imidazole or 1,2,4-triazole or a salt thereof to produce the present compound. This is a method for obtaining the azole derivative (1) of the present invention.
The phenacyl derivative (2) is obtained, for example, by reacting an aryl alcohol (4) with 2-halogeno-2,2-difluoroacetic acid ester (6) to give a compound (5), and converting the compound (5) into a halogenodifluorobenzene ( 7), and the compound (7) is reacted with 2-halogeno-2,2-difluoroacetic acid ester (6 ′) to give a compound (8), and then the aryl alcohol ( It can also be obtained by a method of reacting with 4). The details will be described below.
[0040]
Compound (5) can be produced by reacting aryl alcohol (4) with 2-halogeno-2,2-difluoroacetic acid ester (6) in the presence of a base. As 2-halogeno-2,2-difluoroacetate (6), ethyl 2-chloro-2,2-difluoroacetate, ethyl 2-bromo-2,2-difluoroacetate and the like are commercially available. Can be used. As the base, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, pyridine, triethylamine, isopropylethylamine and the like can be used. Sodium hydride is preferred. As the reaction solvent, methanol, ethanol, diethyl ether, a mixed solvent of methanol and diethyl ether, dimethyl sulfoxide, N, N-dimethylformamide, 1,4-dioxane, tetrahydrofuran and the like can be used, and dimethyl sulfoxide is preferable.
[0041]
The phenacyl derivative (2) can be produced by reacting the compound (5) with a halogenodifluorobenzene (7) in the presence of a base. As the base, n-butyllithium, t-butyllithium, lithium diisopropylamide and the like can be used, but n-butyllithium is preferable. As a reaction solvent, diethyl ether, tetrahydrofuran and the like can be used, and diethyl ether is preferable. The reaction temperature is preferably from -78 to 0C.
[0042]
Compound (8) is obtained by reacting compound (7) with compound (6 ') by a method similar to the above-mentioned method for producing compound (2) from compound (5).
The phenacyl derivative (2) can be produced by reacting the compound (8) with an aryl alcohol (4) in the presence of a base. As the base, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, pyridine, triethylamine, isopropylethylamine and the like can be used. Potassium carbonate is preferred. As the reaction solvent, methanol, ethanol, diethyl ether, a mixed solvent of methanol and diethyl ether, acetonitrile, dimethyl sulfoxide, N, N-dimethylformamide, 1,4-dioxane, tetrahydrofuran and the like can be used, and acetonitrile is preferable.
[0043]
The oxirane derivative (3) is obtained by reacting the phenacyl derivative (2) with 1-2 equivalents of an epoxymethylene agent such as trimethylsulfoxonium iodide or trimethylsulfonium iodide in the presence of 1 to 5 equivalents of a base. Can be obtained by As the base, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, potassium carbonate, sodium hydride and the like can be used, and sodium hydride is preferable. As the solvent, dimethyl sulfoxide, tetrahydrofuran and the like can be suitably used. The reaction temperature is preferably in the range of -100C to the boiling point of the solvent, and more preferably -40C to 50C.
[0044]
Compound (1) of the present invention can be produced by reacting compound (3) with imidazole, 1,2,4-triazole (9) or an alkali metal salt thereof in the presence of a base. As the reaction solvent, N, N-dimethylformamide, acetonitrile, N, N-dimethylacetamide, dimethylsulfoxide and the like can be used, and N, N-dimethylformamide is preferable. As the base, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium carbonate, potassium carbonate, potassium tert-butoxide and the like can be used, and potassium carbonate is preferable. The reaction temperature is preferably in the range of 0 ° C to the boiling point of the solvent, and more preferably 20 to 60 ° C.
The compound (1) can be alkylated, if necessary, with a tertiary hydroxyl group in the presence of a base.
[0045]
[Production method 2]
[0046]
Embedded image
[0047]
[Wherein, X has the same meaning as described above; R has the same meaning as described above.] ]
[0048]
Compound (1) -1 in which Ar is a 4-bromophenyl group in compound (1) of the present invention is described in J. Am. Am. Chem. Soc. , 124, 14844-14855 (2002); Am. Chem. Soc. , 124, 11684-11688 (2002), Organic Letters, 5, 793-796 (2003), Organic Letters, 3, 4295-4298 (2001), and various palladium or copper catalysts. By combining with a ligand compound to form iodination or a carbon-carbon bond or a carbon-nitrogen bond, the compound (1) -2 into which various substituents (R) are introduced can be converted.
[0049]
Iodination can be performed, for example, by reacting compound (1) -1 with copper iodide and sodium iodide in the presence of a ligand. As the ligand, trans-N, N-dimethyl-1,2-cyclohexanediamine, ethylenediamine, N, N'-dimethylethylenediamine, 1,3-diaminopropane, trans-1,2-diaminocyclohexane
And the like. As a reaction solvent, 1,4-dioxane, N, N-dimethylformamide, pyridine, tetrahydrofuran and the like can be used, and 1,4-dioxane is preferable. The reaction temperature is preferably from room temperature to the boiling point of the solvent.
[0050]
As a palladium catalyst, Pd2(Dba)3: Tris (dibenzylideneacetone) -dipalladium (0), Pd (PPh)4: Tetrakis (triphenylphosphine) palladium (0), PdCl2(PPh3)2 : Trans-dichlorobis (triphenylphosphine) palladium (II) and the like.
Examples of the ligand compound include 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl (BINAP), 1,1′-2-binaphthol (BINOL), and 2,2′-bis (oxazolyl) Binaphthyl (BOXAX), 2-dicyclohexylphosphino-2 '-(N, N-dimethylamino) biphenyl, trans-N, N-dimethyl-1,2-cyclohexanediamine, 2,2'-bis (di-p- (Tril-phosphino) -1,1′-binaphthyl (Tol-BINAP), 1 ′, 2-bis (diphenylphosphino) -1- (N, N-dimethylaminoethyl) ferrocene (BPPFA), (−)-( 2S, 4S) -2-diphenylphosphinomethyl-4-diphenylphosphino-1-t-butoxycarbonylpyrrolidine (BPPM), 2,3- (Diphenylphosphino) -bicyclo [2.2.1] hept-5-ene (NORPHOS), 1,2-bis (diphenylphosphino) propane (PROPHOS), O-isopropylidene-2,3-dihydroxy- 1,4-bis (diphenylphosphino) butane (DIOP), 1,3-bis (1-adamantyl) imidazole-2-ylidene (ICy), 1,3-bis (2,4,6-trimethylphenyl) imidazole -2-ylidene (IMes) and the like.
[0051]
The means for isolating the target compound from the reaction mixture after the above reaction is not particularly limited, and for example, can be carried out by solvent extraction, recrystallization, column chromatography, or the like. The conversion of the target compound into a desired salt can also be carried out according to a conventional method.
[0052]
The compound (1) of the present invention has an enantiomer based on an asymmetric carbon atom, and the optically active substance can be produced by separation using an optical isomer separation column. The optically active substance can also be produced by an optical resolution method. The column for separating optical isomers and the optical resolving agent are described in JP-A-11-279160, JP-A-11-240871, and the like.
[0053]
Pharmaceutical compositions containing one or more of the compound (1) or a salt thereof of the present invention as an active ingredient are usually prepared using tablets, powders, It is prepared into fine granules, granules, capsules, pills, solutions, injections, suppositories, vaginal preparations, ointments, patches and the like, and is orally or parenterally administered.
To produce a solid preparation, an excipient and, if necessary, a binder, a disintegrant, a bulking agent, a coating agent, a sugar-coating agent and the like are added to the compound (1) of the present invention. Preference is given to granules, capsules, suppositories and the like. When preparing an injection, the compound (1) of the present invention may be previously dissolved, dispersed, emulsified, or the like in an aqueous carrier such as distilled water for injection to prepare a liquid, or mixed with an injection powder for dissolution at the time of use. Just fine. Examples of the method for administering the injection include intravenous administration, intraarterial administration, intraperitoneal administration, subcutaneous administration, and intravenous infusion.
[0054]
The dose of the compound of the present invention to humans varies depending on the state of infection and the method of administration. For example, when administered to an adult patient for the purpose of treating Candida infection, oral administration of about 0.01 to 100 mg / kg / day. , Preferably about 0.1 to 50 mg / kg / day. More preferably, it is about 1 to 20 mg / kg / day.
[0055]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Reference Examples and Examples, but the present invention is not limited thereto.
[0056]
Reference Example 1 Ethyl 2- (4-bromophenoxy) -2,2-difluoroacetate
21.4 g (0.12 mol) of p-bromophenol was dissolved in 150 ml of DMSO, and 5.45 g (0.14 mol) of 60% NaH was added at room temperature, followed by stirring for 15 minutes. After returning to room temperature, 21.6 g (0.14 mol) of ethyl 2-chloro-2,2-difluoroacetate was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (hexane: ethyl acetate = 5: 1) to obtain 25.4 g (yield: 69.4%) of the desired product as a pale yellow oil.
[0057]
Reference Example 2 Ethyl 2- (4-chlorophenoxy) -2,2-difluoroacetate
The title compound was obtained in the same manner as in Reference Example 1 (hereinafter, the same applies to Reference Example 12).
Pale yellow oil: yield 49.9%
[0058]
Reference Example 3 Ethyl 2,2-difluoro-2- (2-fluorophenoxy) acetate
Pale yellow oil: yield 46.2%
[0059]
Reference Example 4 Ethyl 2,2-difluoro-2- (3-fluorophenoxy) acetate
Colorless oil: yield 32.9%
[0060]
Reference Example 5 Ethyl 2,2-difluoro-2- (4-fluorophenoxy) acetate
Pale yellow oil: 55.5%
[0061]
[Reference Example 6] Ethyl 2,2-difluoro-2- (2-methoxyphenoxy) acetate
Colorless oil: yield 38.8%
[0062]
Reference Example 7 Ethyl 2,2-difluoro-2- (3-methoxyphenoxy) acetate
Colorless oil: 70.0% yield
[0063]
[Reference Example 8] Ethyl 2,2-difluoro-2- (4-methoxyphenoxy) acetate
Colorless oil: yield 81.6%
[0064]
[Reference Example 9] Ethyl 2- [4- (benzyloxy) phenoxy] -2,2-difluoroacetate
Pale yellow oil: yield 66.7%
[0065]
[Reference Example 10] ethyl 2-([1,1'-biphenyl] -4-yloxy) -2,2-difluoroacetate
Colorless crystals: yield 50.0%
[0066]
[Reference Example 11] Ethyl 2,2-difluoro-2- (3-pyridinyloxy) acetate
Light brown oil: Yield 27.4%
[0067]
[Reference Example 12] Ethyl 2- (4-bromo-2-fluorophenoxy) -2,2-difluoroacetate
Colorless oil: 50.0% yield
[0068]
[Reference Example 13] 2- (4-bromophenoxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
16.6 g (0.086 mol) of 1-bromo-2,4-difluorobenzene was dissolved in 300 ml of diethyl ether, and 36.4 ml (0.095 mol) of n-butyllithium (2.6 M hexane solution) was added at -78 ° C. Was added dropwise and stirred at the same temperature for 1 hour. Then, at the same temperature, a solution of 25.4 g (0.086 mol) of 2- (4-bromophenoxy) -2,2-difluoroacetate in 30 ml of diethyl ether was added dropwise, and the mixture was stirred at -78 ° C for 1 hour, and then stirred at room temperature. The temperature was increased until the mixture was stirred for 2 hours. After completion of the reaction, a saturated aqueous solution of ammonium chloride was added, extracted with diethyl ether, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (hexane: ethyl acetate = 100: 1) to obtain 25.0 g of the desired product as a colorless oil (yield: 80.0%).
[0069]
[Reference Example 14] 2- (4-bromophenoxy) -1- (2,5-difluorophenyl) -2,2-difluoro-1-ethanone
The title compound was obtained in the same manner as in Reference Example 13 (the same applies hereinafter to Reference Example 27).
Pale yellow oil: yield 69.8%
[0070]
[Reference Example 15] 2- (4-chlorophenoxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
Pale yellow oil: 84.5% yield
[0071]
[Reference Example 16] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (2-fluorophenoxy) -1-ethanone
Pale yellow oil: 85.8% yield
[0072]
[Reference Example 17] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (3-fluorophenoxy) -1-ethanone
Pale yellow oil: 81.6% yield
[0073]
[Reference Example 18] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (4-fluorophenoxy) -1-ethanone
Pale yellow oil: yield 75.0%
[0074]
[Reference Example 19] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (2-methoxyphenoxy) -1-ethanone
Pale yellow oil: 93.5% yield
[0075]
[Reference Example 20] 1- (2,5-difluorophenyl) -2,2-difluoro-2- (4-fluorophenoxy) -1-ethanone
Pale yellow oil: yield 74.5%
[0076]
[Reference Example 21] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (3-methoxyphenoxy) -1-ethanone
Pale yellow oil: yield 81.2%
[0077]
[Reference Example 22] 1- (2,4-difluorophenyl) -2,2-difluoro-2- (4-methoxyphenoxy) -1-ethanone
Pale yellow oil: yield 97.7%
[0078]
[Reference Example 23] 2- (4-bromo-2-fluorophenoxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
Pale yellow crystal: yield 97.1%
[0079]
[Reference Example 24] 2-([1,1'-biphenyl] -4-yloxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
Pale yellow crystal: yield 55.6%
[0080]
[Reference Example 25] 2- [4- (benzyloxy) phenoxy] -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
Colorless crystals: 76.8% yield
[0081]
[Reference Example 26] 2- [4- (tert-butyl) phenoxy] -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
Pale yellow oil: yield 80.3%
[0082]
[Reference Example 27] 1- (2,4-difluorophenoxy) -2,2-difluoro-2- (3-pyridinyloxy) -1-ethanone
Pale yellow oil: yield 62.8%
[0083]
[Reference Example 28] 2-bromo-1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
19.3 g (0.10 mol) of 1-bromo-2,4-difluorobenzene was dissolved in 300 ml of diethyl ether, and 40 ml (0.10 mol) of n-butyllithium (2.6 M hexane solution) was added dropwise at -78 ° C. Then, the mixture was stirred at the same temperature for 1 hour. Then, at the same temperature, a solution of 20.3 g (0.10 mol) of ethyl 2-bromo-2,2-difluoroacetate in 30 ml of diethyl ether was added dropwise, and the mixture was stirred at -78 ° C for 1 hour, and then raised to room temperature for 2 hours. Stirred. After completion of the reaction, a saturated aqueous solution of ammonium chloride was added, extracted with diethyl ether, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue is purified by distillation, bpThirteen
15.7 g (yield 57.8%) of a 84 ° C fraction as a colorless oil was obtained.
[0084]
[Reference Example 29] 2- (4-bromophenoxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
8.65 g of 4-bromophenol is dissolved in 150 ml of acetonitrile, 6.9 g (0.05 mol) of potassium carbonate is added, and 2-bromo-1- (2,4-difluorophenyl) -2,2-difluoro- is stirred. 13.6 g (0.05 mol) of 1-ethanone was added, and the mixture was stirred at room temperature for 38 hours. After completion of the reaction, insolubles were removed by filtration, and the filtrate was concentrated. The residue was dissolved by adding ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated.
The residue was purified by silica gel chromatography (hexane: ethyl acetate = 100: 1) to obtain 15.7 g of the desired product as a colorless oil (yield: 86.3%).
[0085]
Reference Example 30 2- (1,3-benzenedioxol-5-yloxy) -1- (2,4-difluorophenyl) -2,2-difluoro-1-ethanone
The title compound was obtained in the same manner as in Reference Example 29 (hereinafter, the same applies to Reference Example 31).
Colorless oil: 58.9% yield
[0086]
[Reference Example 31] 4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-oxoethoxy] benzaldehyde O-methyloxime
Yellow oil: 88.0% yield
[0087]
[Reference Example 32] 2-[(4-bromophenoxy) (difluoro) methyl] -2- (2,4-difluorophenyl) oxirane
8.58 g (0.039 mol) of trimethylsulfoxonium iodide was suspended in 50 ml of DMSO, 1.56 g (0.039 mol) of 60% NaH was added, and the mixture was stirred at 50 ° C. for 0.5 hour. Next, a solution of 10.9 g (0.03 mol) of 2- (4-bromophenoxy) -1- (2,4-difluoro) -1-ethanone in 15 ml of DMSO was added dropwise at 50 ° C., and the mixture was stirred for 0.5 hour. . After completion of the reaction, the reaction product was poured into ice water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (hexane: ethyl acetate = 100: 1) to obtain 7.26 g (yield: 64.2%) of the desired product as a pale yellow oil.
[0088]
[Reference Example 33] 2-[(4-bromophenoxy) (difluoro) methyl] -2- (2,5-difluorophenyl) oxirane
The title compound was obtained in the same manner as in Reference Example 32 (hereinafter, the same applies to Reference Example 47).
Pale yellow oil: 75.3% yield
[0089]
[Reference Example 34] 2-[(4-chlorophenoxy) (difluoro) methyl] -2- (2,4-difluorophenyl) oxirane
Pale red oil: yield 92.2%
[0090]
[Reference Example 35] 2- [difluoro (2-fluorophenoxy) methyl] -2- (2,4-difluorophenyl) oxirane
Pale red oil: 81.4% yield
[0091]
[Reference Example 36] 2- [difluoro (3-fluorophenoxy) methyl] -2- (2,4-difluorophenyl) oxirane
Light brown oil: 81.4% yield
[0092]
[Reference Example 37] 2- [difluoro (4-fluorophenoxy) methyl] -2- (2,4-difluorophenyl) oxirane
Pale yellow oil: yield 60.1%
[0093]
[Reference Example 38] 2- [difluoro (4-fluorophenoxy) methyl] -2- (2,5-difluorophenyl) oxirane
Pale yellow oil: yield 90.0%
[0094]
[Reference Example 39] 2-[[2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methoxy] phenyl methyl ether
Pale yellow oil: yield 65.0%
[0095]
[Reference Example 40] 3-[[2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methoxy] phenyl methyl ether
Pale yellow oil: yield 97.5%
[0096]
[Reference Example 41] 4-[[2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methoxy] phenyl methyl ether
Pale yellow oil: yield 39.7%
[0097]
[Reference Example 42] 4-bromo-2-fluorophenyl [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl ether
Pale yellow oil: yield 42.6%
[0098]
[Reference Example 43] [1,1'-biphenyl] -4-yl [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl ether
Light brown crystal: yield 61.5%
[0099]
[Reference Example 44] 2-[[4- (benzyloxy) phenoxy] (difluoro) methyl] -2- (2,4-difluorophenyl) oxirane
Pale yellow oil: yield 64.6%
[0100]
[Reference Example 45] 4- (tert-butyl) phenyl [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl ether
Colorless oil: 75.3% yield
[0101]
[Reference Example 46] 1,3-benzenedioxol-5-yl [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl ether
Colorless oil: 47.4% yield
[0102]
[Reference Example 47] [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl 3-pyridinyl ether
Light brown oil: 99.0% yield
[0103]
[Example 1] 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 10) 8.19 g (0.022 mol) of 2-[(4-bromophenoxy) (difluoro) methyl] -2- (2,4-difluorophenyl) oxirane was dissolved in 43 ml of DMF. 2.25 g (0.033 mol) of 2,4-triazole and 4.50 g (0.033 mol) of potassium carbonate were added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (chloroform: methanol = 50: 1) to give 4.60 g (yield 47.5%) of the desired product as colorless crystals.
[0104]
Melting point: 110-111 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.2 Hz), 5.31 (1H, d, J = 14.2 Hz), 5.65 (s, 1H), 6.78 (m, 1H) , 6.90 (m, 1H), 6.96 (2H, d, J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.84 (m, 1H), 7 .88 (s, 1H), 8.16 (s, 1H).
[0105]
Example 2 2- (2,4-difluorophenyl) -1,1-difluoro-1-phenoxy-3- (1H-1,2,4-triazol-1-yl) -2-propanol (compound number 4)
The title compound was obtained in the same manner as in Example 1 (hereinafter the same up to Example 18).
Colorless crystals: 24.0% yield
Melting point: 114-119 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.95 (2H, d, J = 14.2 Hz), 5.32 (1H, d, J = 14.2 Hz), 5.6681H, s), 6.75-6.81 (1H, m), 6.87-6.91 (1H, m), 7.07 (2H, d, J = 8.30 Hz), 7.18-7.33 (3H, m), 7.82-7. 86 (1H, m), 7.86 (1H, s), 8.16 (1H, s).
[0106]
Example 3 2- (2,4-difluorophenyl) -1,1-difluoro-1- (2-fluorophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 5)
Colorless crystals: 55.5% yield
Melting point: 93-94 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 5.00 (1H, d, J = 14.2 Hz), 5.36 (1H, d, J = 14.2 Hz), 5.69 (1H, s), 6.74-6.80 ( 1H, m), 6.88-6.93 (1H, m), 7.07-7.23 (4H, m), 7.84-7.90 (2H, m), 8.18 (1H, m). s).
[0107]
Example 4 2- (2,4-difluorophenyl) -1,1-difluoro-1- (3-fluorophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 6)
Colorless crystals: 20.9% yield
Melting point: 113-115 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.6 Hz), 5.31 (1H, d, J = 14.6 Hz), 5.67 (1H, s), 6.76-6.96 ( 5H, m), 7.26-7.31 (1H, m), 7.82-7.89 (2H, m), 8.16 (1H, s).
[0108]
Example 5 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-fluorophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 7)
Colorless crystals: yield 39.9%
Melting point: 97-98 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.2 Hz), 5.31 (1H, d, J = 14.2 Hz), 5.65 (1H, s), 6.75-7.05 ( 6H, m), 7.82-7.88 (2H, m), 8.16 (1H, s).
[0109]
Example 6 2- (2,5-difluorophenyl) -1,1-difluoro-1- (4-fluorophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 8)
Colorless oil: 50.0% yield
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.94 (1H, d, J = 14.2 Hz), 5.34 (1H, d, J = 14.2 Hz), 5.73 (1H, s), 6.97-7.06 ( 6H, m), 7.55-7.59 (1H, m), 7.8 (1H, s), 8.16 (1H, s).
[0110]
Example 7 1- (4-Chlorophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 9)
Colorless crystals: yield 62.2%
Melting point: 98-100 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.2 Hz), 5.31 (1H, d, J = 14.2 Hz), 5.68 (1H, s), 6.75-6.81 ( 1H, m), 6.88-6.93 (1H, m), 7.01 (2H, d, J = 9.3 Hz), 7.28 (2H, d, J = 9.3 Hz), 7. 82-7.88 (2H, m), 8.15 (1H, s).
[0111]
Example 8 1- (4-Bromophenoxy) -2- (2,5-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 11) colorless oil: yield 77.2%
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.7 Hz), 5.34 (1H, d, J = 14.7 Hz), 5.77 (1H, s), 6.99 (4H, m) , 7.44 (2H, m), 7.57 (1H, m), 7.89 (1H, s), 8.16 (1H, s).
[0112]
Example 9 4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] phenol ( Compound No. 13) The compound obtained in Example 11 described later was debenzylated by a conventional method to give the desired product as colorless crystals.
Yield: 85.4% yield
Melting point: 127-128 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.97 (1H, d, J = 14.2 Hz), 5.28 (1H, d, J = 14.2 Hz), 5.46 (1H, s), 5.54 (1H, s) , 6.74-6.81 (3H, m), 6.88-6.93 (3H, m), 7.82-7.89 (2H, m), 8.18 (1H, s).
[0113]
Example 10 1- [4- (benzyloxy) phenoxy] -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl ) -2-Propanol (Compound No. 14)
Colorless crystals: yield 44.0%
Melting point: 104-105 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.94 (1H, d, J = 14.2 Hz), 5.02 (2H, s), 5.30 (1H, d, J = 14.2 Hz), 5.57 (1H, s) , 6.74-6.99 (6H, m), 7.31-7.42 (5H, m), 7.82-7.88 (2H, m), 8.16 (1H, s).
[0114]
Example 11 2- (2,4-difluorophenyl) -1,1-difluoro-1- (2-methoxyphenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 15)
Colorless crystals: 55.3% yield
Melting point: 125-127 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm:
3.80 (3H, s), 5.01 (1H, d, J = 14.7 Hz), 5.37 (1H, d, J = 14.7 Hz), 5.43 (1H, s), 6. 75-6.95 (4H, m), 7.13-7.21 (2H, m), 7.81-7.87 (2H, m), 8.19 (1H, s).
[0115]
Example 12 2- (2,4-difluorophenyl) -1,1-difluoro-1- (3-methoxyphenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 16)
Colorless crystals: 52.5% yield
Melting point: 116-119 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.78 (3H, s), 4.47 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5.62 (1H, s) , 6.61-6.92 (5H, m), 7.21 (1H, dd, J = 8.3, 8.3 Hz), 7.82-7.88 (2H, m), 8.16 ( 1H, s).
[0116]
Example 13 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-methoxyphenoxy) -3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 17)
Colorless crystals: 10.2% yield
Melting point: 114-116 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.78 (3H, s), 4.94 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5.58 (1H, s) , 6.75-6.92 (4H, m), 6.98 (2H, d, J = 9.3 Hz), 7.82-7.88 (2H, m), 8.16 (1H, s). .
[0117]
[Example 14] 1- (4-bromo-2-fluorophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazole-1- Yl) -2-propanol (Compound No. 18)
Colorless crystals: 30.6% yield
Melting point: 97-98 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.97 (1H, d, J = 14.1 Hz), 5.34 (1H, d, J = 14.1 Hz), 5.73 (1H, s), 6.74-6.80 ( 1H, m), 6.88-6.93 (1H, m), 7.07-7.11 (1H, m), 7.23-7.33 (2H, m), 7.82-7. 87 (1H, m), 7.88 (1H, s), 8.17 (1H, s).
[0118]
Example 15 4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] benzaldehyde O -Methyl oxime (Compound No. 41)
Pale yellow oil: yield 5.0%
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.95 (3H, s), 4.94 (1H, d, J = 14.2 Hz), 5.32 (1H, d, J = 14.2 Hz), 5.70 (1H, s) , 6.75-6.92 (2H, m), 7.07 (2H, d, J = 8.30 Hz), 7.53 (2H, d, J = 8.30 Hz), 7.82-7. 89 (1H, m), 7.87 (1H, s), 8.01 (1H, s), 8.16 (1H, s).
[0119]
Example 16 1- [4- (tert-butyl) phenoxy] -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazole-1- Yl) -2-propanol (Compound No. 42)
Colorless crystals: 59.6% yield
Melting point: 168-169 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 1.29 (9H, s), 4.95 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5.59 (1H, s) , 6.74-6.80 (1H, m), 6.87-6.91 (1H, m), 6.98 (2H, d, J = 8.8 Hz), 7.32 (2H, d, J = 8.8 Hz), 7.82-7.88 (2H, m), 8.17 (1H, s).
[0120]
Example 17 1-([1,1′-biphenyl] -4-yloxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 45)
Colorless crystals: yield 36.5%
Melting point: 135-137 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.98 (1H, d, J = 14.1 Hz), 5.35 (1H, d, J = 14.1 Hz), 5.63 (1H, s), 6.77-6.82 ( 1H, m), 6.89-6.93 (1H, m), 7.14 (2H, d, J = 8.3 Hz), 7.33-7.36 (1H, m), 7.41- 7.45 (2H, m), 7.52-7.55 (4H, m), 7.85-7.91 (2H, m), 8.18 (1H, s).
[0121]
Example 18 2- (2,4-difluorophenyl) -1,1-difluoro-1- (3-pyridinyloxy) -3- (1H-1,2,4-triazol-1-yl) -2- Propanol (Compound No. 47) light brown crystal: yield 8.0%
Melting point: 110-113 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.95 (1H, d, J = 14.1 Hz), 5.34 (1H, d, J = 14.1 Hz), 5.75 (1H, s), 6.77-6.82 ( 1H, m), 6.89-6.93 (1H, m), 7.26-7.31 (1H, m), 7.43-7.45 (1H, m), 7.83-7. 88 (1H, m), 7.88 (1H, s), 8.17 (1H, s), 8.40 (1H, d, J = 2.4 Hz), 8.47-8.48 (1H, m).
[0122]
Example 19 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-imidazol-1-yl) -2-propanol (Compound No. 2) )
A mixture of 0.19 g (0.5 mmol) of 2-[(4-bromophenoxy) (difluoro) methyl] -2- (2,4-difluorophenyl) oxirane and 0.068 g (1.0 mmol) of imidazole was added at 90 ° C. Stir for 1 hour. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (chloroform: methanol = 50: 1) to obtain 0.12 g (yield: 54.5%) of the desired product as colorless crystals.
[0123]
Melting point: 146-150 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.66 (1H, d, J = 14.7 Hz), 5.01 (1H, d, J = 14.7 Hz), 6.46 (1H, s), 6.74 (1H, s) , 6.84-6.95 (2H, m), 6.98 (2H, d, J = 8.8 Hz), 7.38 (1H, s), 7.42-7.46 (2H, m) , 7.81-7.87 (1H, m).
[0124]
Example 20 1- (4-chlorophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-imidazol-1-yl) -2-propanol (Compound No. 1) )
The title compound was obtained in the same manner as in Example 19.
Colorless crystals: yield 54.1
Melting point: 147-151 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.64 (1H, d, J = 14.7 Hz), 5.03 (1H, d, J = 14.7 Hz), 6.35 (1H, s), 6.69 (1H, s) , 6.84-6.94 (2H, m), 7.03 (2H, d, J = 8.8 Hz), 7.29 (2H, d, J = 8.8 Hz), 7.38 (1H, m). s), 7.87-7.93 (1H, m), 8.01 (1H, brs).
[0125]
Example 21 1- (4-Bromophenoxy) -2- (2,5-difluorophenyl) -1,1-difluoro-3- (1H-imidazol-1-yl) -2-propanol (Compound No. 3) )
The title compound was obtained in the same manner as in Example 19.
Colorless crystals: 52.1% yield
Point: 128-130 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.66 (1H, d, J = 14.6 Hz), 5.02 (1H, d, J = 14.6 Hz), 6.54 (1H, brs), 6.77 (1H, brs) , 6.99 (2H, d, J = 8.8 Hz), 7.05-7.12 (2H, m), 7.43-7.46 (3H, m), 7.52-7.59 ( 1H, m).
[0126]
Example 22 1- (1,3-benzenedioxol-5-yloxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 19)
1,3-benzenedioxol-5-yl [2- (2,4-difluorophenyl) -2-oxiranyl] (difluoro) methyl ether 1.64 g (5 mmol), 1,2,4-triazole 0.49 g (A 7.1 mmol mixture was stirred at 120 ° C. for 1 hour. After the reaction was completed, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate, and evaporated. The residue was purified by silica gel chromatography (chloroform: methanol = 50: 1) to obtain 0.33 g (yield: 35.1%) of the target compound as colorless crystals.
[0127]
Melting point: 108-110 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.1 Hz), 5.30 (1H, d, J = 14.1 Hz), 5.58 (1H, s), 5.97 (2H, s) , 6.51-6.53 (1H, m), 6.57 (1H, d, J = 2.0 Hz), 6.70 (1H, d, J = 8.3 Hz), 6.75-6. 81 (1H, m), 6.87-6.91 (1H, m), 7.81-7.85 (1H, m), 7.86 (1H, s), 8.16 (1H, s) .
[0128]
Example 23 2- (2,4-difluorophenyl) -1,1-difluoro1- [4- (4-phenylpiperazino) phenoxy] -3- (1H-1,2,4-triazole- 1-yl) -2-propanol (Compound No. 31)
0.223 g of 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2-propanol (0.5 mmol), 0.086 ml (0.56 mmol) of 1-phenylpiperazine, Pd2(Dba)3 (Pd2(Dba)3: Tris (dibenzylideneacetone) -dipalladium (0)) 0.0046 g (0.005 mmol), BINAP (BINAP: 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl) 0.0094 g ( 0.015 mmol), 0.135 g (1.4 mmol) of sodium t-butoxide, and 2.5 ml of toluene were stirred at 80 ° C. for 16 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 1: 1) to give 0.085 g (yield 32.0%) of the desired product as colorless crystals.
[0129]
Melting point: 97-105 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.28-3.33 (8H, m), 4.95 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5. 54 (1H, s), 6.75-6.81 (1H, m), 6.88-6.91 (4H, m), 6.97-6.99 (4H, m), 7.26- 7.31 (2H, m), 7.82-7.87 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0130]
Example 24 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-piperidinophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (Compound No. 27)
The title compound was obtained in the same manner as in Example 23 (hereinafter the same up to Example 33).
Colorless crystals: yield 50.0%
Melting point: 137-142 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 1.52-1.58 (2H, m), 1.66-1.71 (4H, m), 3.09 (4H, t, J = 5.7 Hz), 4.94 (1H , D, J = 14.6 Hz), 5.31 (1H, d, J = 14.6 Hz), 5.50 (1H, s), 6.99-6.73 (6H, m), 7 .81-7.87 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0131]
Example 25 2- (2,4-Difluorophenyl) -1,1-difluoro-1- (4-morpholinophenoxy) -3- (1H-1,2,4-triazol-1-yl)- 2-propanol (Compound No. 28)
Colorless crystals: 27.0% yield
Melting point: 115-119 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.09-3.11 (4H, m), 3.83-3.85 (4H, m), 4.94 (1H, d, J = 14.2 Hz), 5.30 (1H, m) d, J = 14.2 Hz), 5.55 (1H, s), 6.75-6.98 (2H, m), 6.82 (2H, d, J = 8.8 Hz), 6.97 ( 2H, d, J = 8.8 Hz), 7.81-7.85 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0132]
Example 26 4- [4- [2-hydroxy-2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) propoxy ] Phenyltetrahydro-1 (2H) -pyrazine] tert-butyl carboxylate (Compound No. 30)
Colorless crystals: yield 64.0%
Melting point: 130-134 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 1.47 (9H, s), 3.05-3.08 (4H, m), 3.54-3.57 (4H, m), 4.94 (1H, d, J = 14. 7 Hz), 5.31 (1H, d, J = 14.7 Hz), 5.56 (1H, s), 6.74-6.91 (2H, m), 6.84 (2H, d, J = 7.3 Hz), 6.96 (2H, de, J = 7.3 Hz), 7.81-7.85 (1H, m), 7.87 (1H, s), 8.16 (1H, s) .
[0133]
Example 27 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (4-fluorophenyl) piperazinophenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 32)
Colorless crystals: 17.9% yield
Melting point: 97-98 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.23-3.30 (8H, m), 4.95 (1H, d, J = 14.2 Hz), 5.32 (1H, d, J = 14.2 Hz), 5.57 ( 1H, s), 6.75-7.01 (10H, m), 7.82-7.88 (2H, m), 8.17 (1H, s).
[0134]
Example 28 2- (2,5-difluorophenyl) -1,1-difluoro-1- [4- (4-fluorophenyl) piperazinophenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 33)
Colorless crystals: 48.3% yield
Melting point: 156-158 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.23-3.30 (8H, m), 4.95 (1H, d, J = 14.2 Hz), 5.35 (1H, d, J = 14.2 Hz), 5.62 ( 1H, s), 6.88-7.01 (10H, m), 7.55-7.60 (1H, m), 7.89 (1H, s), 8.16 (1H, s).
[0135]
Example 29 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (4-nitrophenyl) piperazinophenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 34)
Yellow crystals: 25.9% yield
Melting point: 150-154 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.29-3.31 (4H, m), 3.56-3.59 (4H, m), 4.96 (1H, d, J = 14.7 Hz), 5.31 (1H, d, J = 14.7 Hz), 5.58 (1H, s), 6.75-6.81 (1H, m), 6.85-6.92 (5H, m), 6.98-7. 01 (2H, m), 7.82-7.88 (2H, m), 8.13-8.17 (3H, m).
[0136]
Example 30 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (3-methoxyphenyl) piperazinophenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 35)
Colorless crystals: yield 6.3%
Melting point: 134-137 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.26-3.33 (8H, m), 3.80 (3H, s), 4.95 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5.55 (1H, s), 6.44-6.60 (3H, m), 6.75-7.00 (6H, m), 7.20 (1H, dd, J = 8.3, 8.3 Hz), 7.82-7.88 (2H, m), 8.16 (1H, s).
[0137]
Example 31 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (3-chlorophenyl) piperazinophenoxy] -3- (1H-1,2,4-triazole -1-yl) -2-propanol (Compound No. 36)
Colorless crystals: 7.8% yield
Melting point: 123-126 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.26-3.34 (8H, m), 4.95 (1H, d, J = 14.7 Hz), 5.32 (1H, d, J = 14.7 Hz), 5.56 ( 1H, s), 6.75-7.00 (9H, m), 7.19 (1H, dd, J = 8.3, 8.3 Hz), 7.86 (2H, m), 8.16 ( 1H, s).
[0138]
Example 32 4- [4- (2-Hydroxy-2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) propoxy) Phenyl] -1- (4-methoxyphenyl) tetrahydro-2 (1H) -pyrazinone (Compound No. 37)
Colorless crystals: 31.0% yield
Melting point: 148-152 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.55-3.57 (2H, m), 3.79-3.81 (2H, m), 3.81 (3H, s), 4.00 (2H, bs), 4.94. (1H, d, J = 14.2 Hz), 5.30 (1H, d, J = 14.2 Hz), 5.61 (1H, s), 6.76-6.92 (2H, m), 6 0.83 (2H, d, J = 8.8 Hz), 6.93 (2H, d, J = 8.8 Hz), 7.02 (2H, d, J = 8.8 Hz), 7.21 (2H, d, J = 8.8 Hz), 7.84-7.85 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0139]
Example 33 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-piperazinophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (Compound No. 29)
The compound obtained in Example 26 was debutylated with trifluoroacetic acid by a conventional method to give the desired product as a pale yellow oil.
Yield: 89.0% yield
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.00-0.09 (8H, m), 4.94 (1H, d, J = 14.2 Hz), 5.30 (1H, d, J = 14.2 Hz), 6.74- 6.91 (2H, m), 6.83 (2H, d, J = 9.3 Hz), 6.95 (2H, d, J = 9.3 Hz), 7.80-7.84 (1H, m ), 7.86 (1H, s), 8.15 (1H, s).
[0140]
Example 34 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (3-methoxypropyl) amino] phenyl-3- (1H-1,2,4-triazole- 1-yl) -2-propanol (Compound No. 20)
0.224 g of 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2-propanol 0.5 mmol), 3-methoxypropylamine 0.08 ml (0.78 mmol), copper iodide 0.0057 g (0.03 mmol), N, N-diethyl-2-hydroxybenzamide 0.0195 g (0.1 mmol) A mixture of 0.212 g (1.0 mmol) of tripotassium phosphate and 0.5 ml of 1,4-dioxane was stirred at 90 ° C. for 12 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 2: 1) to give 0.024 g (yield 10.0%) of the desired product as colorless crystals.
[0141]
Melting point: 104-106 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 1.86 (2H, quint, J = 5.8 Hz), 3.17 (2H, t, J = 6.3 Hz), 3.34 (3H, s), 3.49 (2H, t) , J = 6.3 Hz), 4.93 (1H, d, J = 14.1 Hz), 5.30 (1H, d, J = 14.1 Hz), 5.47 (1H, s), 6.49-6.51 (2H, m), 6.73-6.79 (1H, m), 6.84-6.90 (3H, m), 7.80-7.85 (1H, m) ), 7.87 (1H, s), 8.16 (1H, s).
[0142]
Example 35 Methyl (E) -3-4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazole- 1-yl) propoxy] phenyl-2-propenoate (Compound No. 40)
0.446 g of 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2-propanol 1.0 mmol), methyl acrylate 0.1 ml (1.1 mmol), Pd2(Dba)3 0.0135 g (0.015 mmol), [(tBu)3Ph] BF4 ([(TBu)3Ph] BF4: Tri-t-butylphosphonium tetrafluoroborate) A mixture of 0.0088 g (0.03 mmol), dicyclohexylmethylamine 0.24 ml (1.1 mmol), and 1,4-dioxane 1.0 ml at 120 ° C for 12 hours. Stirred. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 2: 1) to obtain 0.209 g (yield: 46.0%) of the desired product as colorless crystals.
[0143]
Melting point: 149-151 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.80 (3H, s), 4.95 (1H, d, J = 14.6 Hz), 5.32 (1H, d, J = 14.6 Hz), 5.67 (1H, s), 6.37 (1H, d, J = 16.1 Hz), 6.75-6.81 (1H, m), 6.88-6.93 (1H, m), 7.09 (2H , D, J = 8.3 Hz), 7.48 (2H, d, J = 8.3 Hz), 7.64 (1H, d, J = 16.1 Hz), 7.82-7.87 (1H, m), 7.88 (1H, s), 8.16 (1H, s).
[0144]
Example 36 2- (2,4-difluorophenyl) -1,1-difluoro-1-[(4′-methoxy [1,1′-biphenyl] -4-yl) oxy] -3- (1H -1,2,4-triazol-1-yl) -2-propanol (Compound No. 46)
0.224 g of 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (H-1,2,4-triazol-1-yl) -2-propanol 0.5 mmol), 0.320 g (0.65 mmol) of 4-methoxyphenylboronic acid, Pd (PPh)4 (Pd (PPh)4: Tetrakis (triphenylphosphine) palladium (0)) A mixture of 0.0345 g (0.03 mmol), 4.5 ml of 2M sodium carbonate, 7 ml of toluene and 0.5 ml of ethanol was stirred at 100 ° C for 12 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 1: 1) to give 0.192 g (yield: 81.0%) of the desired product as colorless crystals.
[0145]
Melting point: 150-152 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.84 (3H, s), 4.97 (1H, d, J = 14.1 Hz), 5.34 (1H, d, J = 14.1 Hz), 5.61 (1H, s), 6.76-6.82 (1H, m), 6.88-6.93 (1H, m), 6.95-6.97 (1H, m), 7.11 (2H, d, J = 8.8 Hz), 7.45-7.49 (4H, m), 7.84-7.89 (1H, m), 7.89 (1H, s), 8.17 (1H, s) ).
[0146]
Example 37 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-iodophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2- Propanol (Compound No. 12)
0.446 g of 1- (4-bromophenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2-propanol 1 mmol), copper iodide 0.00952 g (0.05 mmol), trans-N, N-dimethyl-1,2-cyclohexanediamine 0.0142 g (0.1 mmol), sodium iodide 0.30 g (2 mmol), A mixture of 2 ml of 4-dioxane was stirred at 110 ° C. for 24 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 1: 1) to obtain 0.40 g (yield: 81.0%) of the desired product as colorless crystals.
[0147]
Melting point: 130-132 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 8.15 (1H, s), 7.87 (1H, s), 7.85-7.81 (1H, m), 7.62 (2H, d, J = 8.8 Hz), 6 .96-6.75 (2H, m), 6.83 (2H, d, J = 8.8 Hz), 5.66 (1H, s), 5.30 (1H, d, J = 14.2 Hz) , 4.92 (1H, d, J = 14.2 Hz).
[0148]
[Example 38] 1-4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] Phenyl-2-pyrrolidinone (Compound No. 25)
0.173 g of 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-iodophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (0.35 mmol), 2-pyrrolidinone 0.036 g (0.42 mmol), copper iodide 0.0034 g (0.0175 mmol), tripotassium phosphate 0.15 g (0.7 mmol), trans-N, N-dimethyl A mixture of 0.005 g (0.035 mmol) of -1,2-cyclohexanediamine and 0.35 ml of 1,4-dioxane was stirred at 110 ° C. for 48 hours.
After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 1: 1) to give 0.040 g (yield 25.0%) of the desired product as colorless crystals.
[0149]
Melting point: 106-109 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 2.14 (2H, m), 2.58-2.62 (2H, m), 3.81-3.84 (2H, m), 4.95 (1H, d, J = 14. 7Hz), 5.32 (1H, d, J = 14.7 Hz), 5.63 (1H, s), 6.75-6.91 (2H, m), 7.06 (2H, d, J = 8.8 Hz), 7.57 (2H, d, J = 9.3 Hz), 7.83-7.85 (1H, m), 7.87 (1H, s), 8.16 (1H, s) .
[0150]
[Example 39] N-4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] Benzyl phenylcarbamate (Compound No. 21)
The title compound was obtained in the same manner as in Example 38 (hereinafter, the same applies to Example 43). Colorless crystals: 62.0% yield
Melting point: 139-142 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.93 (1H, d, J = 14.2 Hz), 5.18 (2H, s), 5.30 (1H, d, J = 14.2 Hz), 5.61 (1H, s) , 6.71 (1H, bs), 6.74-6.91 (2H, m), 7.00 (2H, d, J = 8.8 Hz), 7.32-7.38 (8H, m) , 7.80-7.84 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0151]
Example 40 N-4- [1,1-difluoro-2- (2,4-difluorophenyl) -2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] Phenyl-4-methylbenzamide (Compound No. 22)
Colorless crystals: 46.0% yield
Melting point: 111-116 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.13 (3H, s), 4.92 (1H, d, J = 14.7 Hz), 5.37 (1H, d, J = 14.7 Hz), 6.80-6.90 ( 2H, m), 7.09 (2H, d, J = 8.8 Hz), 7.27 (2H, d, J = 7.8 Hz), 7.62 (2H, d, J = 8.8 Hz), 7.70-7.81 (1H, m), 7.79 (2H, d, J = 7.8 Hz), 8.23 (1H, s), 8.79 (1H, s).
[0152]
Example 41 N-4- [1,1-Difluoro-2-hydroxy-2- (2,4-difluorophenyl) -3- (1H-1,2,4-triazol-1-yl) propoxy] Phenyl-4-methylbenzenesulfonamide (Compound No. 23)
Colorless crystals: 17.0% yield
Melting point: 174-176 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 2.37 (3H, s), 4.89 (1H, d, J = 14.2 Hz), 5.30 (1H, d, J = 14.2 Hz), 6.78-6.95 ( 2H, m), 6.94 (2H, d, J = 8.3 Hz), 7.02 (2H, d, J = 8.3 Hz), 7.21 (2H, d, J = 7.8 Hz), 7.60 (2H, d, J = 7.8 Hz), 7.77-7.85 (1H, m), 7.85 (1H, s), 8.17 (1H, s).
[0153]
Example 42 2- [4- [2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy ] Phenyl] -4- (4-methoxyphenyl) -2,4-dihydro-3H-1,2,4-triazol-3-one (Compound No. 24)
The title compound was obtained as colorless crystals in the same manner as in Example 38, except that the reaction solvent was N, N-dimethylformamide, and the reaction time was changed to 16 hours.
[0154]
Yield: 29.0% yield
Melting point: 137-140 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.84 (3H, s), 4.95 (1H, d, J = 14.2 Hz), 5.34 (1H, d, J = 14.2 Hz), 6.76-6.92 ( 2H, m), 7.00 (2H, d, J = 9.3 Hz), 7.15 (2H, d, J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.75 (1H, s), 7.83-7.87 (1H, m), 7.88 (1H, s), 7.99 (2H, d, J = 9.3 Hz), 8.17 ( 1H, s).
[0155]
Example 43 3-4- [2- (2,4-Difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propoxy] Phenyl-1,3-oxazolan-2-one (Compound No. 26)
Colorless crystals: 58.0% yield
Melting point: 85-92 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.01-4.03 (2H, m), 4.46-4.49 (2H, m), 4.94 (1H, d, J = 14.2 Hz), 5.32 (1H, d, J = 14.2 Hz), 5.67 (1H, s), 6.76-6.91 (2H, m), 7.08 (1H, d, J = 8.8z), 7.49 ( 2H, d, J = 8.8z), 7.84-7.87 (1H, m), 7.87 (1H, s), 8.17 (1H, s).
[0156]
Example 44 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (1H-pyrazol-1-yl) phenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 38)
0.493 g of 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-iodophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (1.0 mmol), pyrazole 0.075 g (1.1 mmol), copper iodide 0.019 g (0.1 mmol), tripotassium phosphate 0.425 g (2.0 mmol), trans-N, N-dimethyl-1 A mixture of 0.028 g (0.2 mmol) of 1,2-cyclohexanediamine and 1.0 ml of 1,4-dioxane was stirred at 120 ° C. for 12 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 2: 1) to give 0.342 g (yield: 78.0%) of the desired product as colorless crystals.
[0157]
Melting point: 142-143 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.96 (1H, d, J = 14.1), 5.33 (1H, d, J = 14.1), 5.65 (1H, s), 6.46 (1H, t, J = 2.0), 6.76-6.82 (1H, m), 6.88-6.93 (1H, m), 7.16 (2H, d, J = 8.8), 7. 63-7.66 (2H, m), 7.66 (1H, s), 7.71 (1H, d, J = 2.0), 7.83-7.89 (3H, m), 8. 18 (1H, s).
[0158]
Example 45 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (1H-imidazol-1-yl) phenoxy] -3- (1H-1,2,4- Triazol-1-yl) -2-propanol (Compound No. 39)
The title compound was obtained in the same manner as in Example 44.
Colorless crystals: 32.0% yield
Melting point: 139-141 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 4.97 (1H, d, J = 14.1 Hz), 5.33 (1H, d, J = 14.1 Hz), 5.83 (1H, s), 6.77-6.83 (1H, m), 6.89-6.94 (1H, m), 7.18-7.23 (3H, m), 7.26-7.37 (2H, m), 7.80 (1H , S), 7.84-7.90 (3H, m), 8.17 (1H, s).
[0159]
Example 46 1- (4-allylphenoxy) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4-triazol-1-yl) -2 -Propanol (Compound No. 43)
0.247 g of 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-iodophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (0.5 mmol), allyltributyltin 0.33 ml (1.0 mmol), Pd (PPh)4 (Pd (PPh)4: A mixture of 0.058 g (0.05 mmol) of tetrakis (triphenylphosphine) palladium (0) and 10 ml of toluene was stirred at 120 ° C for 12 hours. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 2: 1) to obtain 0.099 g (yield: 49.0%) of the desired product as colorless crystals.
[0160]
Melting point: 124-126 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 3.35 (1H, d, J = 6.4 Hz 4.95 (1H, d, J = 14.1 Hz 5.03 (1H, m), 5.07 (1H, s), 5.32) (1H, d, J = 14.1 Hz), 5.58 (1H, s), 5.87-5.97
(1H, m), 6.74-6.80 (1H, m), 6.87-6.91 (1H, m), 6.98 (2H, d, J = 8.8 Hz), 7.13 (2H, d, J = 8.8 Hz), 7.82-7.86 (1H, m), 7.87 (1H, s), 8.16 (1H, s).
[0161]
Example 47 2- (2,4-difluorophenyl) -1,1-difluoro-1- [4- (2-phenylethynyl) phenoxy] -3- (1H-1,2,4-triazole-1 -Yl) -2-propanol (Compound No. 44)
0.247 g of 2- (2,4-difluorophenyl) -1,1-difluoro-1- (4-iodophenoxy) -3- (1H-1,2,4-triazol-1-yl) -2-propanol (0.5 mmol), phenylacetylene 0.33 ml (1.0 mmol), PdCl2(PPh3)2 (PdCl2(PPh3)2 : A mixture of trans-dichlorobis (triphenylphosphine) palladium (II)) 0.007 g (0.01 mmol), copper iodide 0.0041 g (0.02 mmol), triethylamine 0.1 ml, and DMF 2 ml at room temperature for 12 hours. Stirred. After completion of the reaction, the reaction solution was poured into water, extracted with ethyl acetate, washed with water, washed with a saturated aqueous solution of sodium chloride, dried over sodium hydrogen sulfate and evaporated. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 2: 1) to obtain 0.178 g (yield: 72.0%) of the desired product as colorless crystals.
[0162]
Melting point: 115-117 ° C
1H-NMR (400 MHz, CDCl3) Δ ppm: 5.96 (1H, d, J = 14.1 Hz 5.33 (1H, d, J = 14.1 Hz 5.64 (1H, s), 6.76-6.82 (1H, m)) , 6.88-6.93 (1H, m), 7.04 (2H, d, J = 8.8 Hz), 7.35 (2H, m), 7.47-7.52 (4H, m) , 7.83-7.89 (1H, m), 7.92 (1H, s), 8.24 (1H, s).
[0163]
[Test Example 1] <Measurement of antifungal activity>
According to NCCLS protocols M37-A2 and M38-A, MIC was measured by the following procedure.
Test compound solution: The test compound is dissolved in dimethyl sulfoxide (DMSO) to a maximum of 6.4.
mg / mL, and diluted with DMSO to prepare a two-fold dilution series.
Test strain:Candida albicans ATCC 90028,C.albicans No. 10675 (fluconazole resistant strain),C.albicans No. 89574 (same),C.krusei ATCC 6258,Aspergillus flavus IFM 41935,A.fumigatus IFM 40808,Trichophyton mentagrophytes IFM 40769 andT.rubrum IFO 6204 was used.
Antifungal activity measurement: Using a test medium, RPMI1640, a DMSO solution of the test compound was diluted 50-fold with the test medium and dispensed 100 μL into predetermined wells of a 96-well round bottom microplate. nextCandidaA genus fungus is suspended in sterile physiological saline, and the turbidity is adjusted to McFarland 0.5, and then diluted 1000-fold with a test medium to obtain an inoculum,AspergillusGenus fungi andTrichophytonThe genus Fungus was 6.0 × 10 6 in the test medium.4 condia / mL and 2.0 × 105 The solution was adjusted to condia / mL to obtain an inoculum. 100 μL of these inoculum was dispensed into predetermined wells of a 96-well round bottom microplate,CandidaGenus fungi andAspergillusGenus fungi at 35 ° C for 48 hours,TrichophytonGenus fungi were cultured at 27 ° C. for 72 hours. After cultivation,CandidaThe absorbance (600 nm) of the genus Fungi was measured, and the MIC (μg / ml) was defined as the minimum drug concentration at which the growth of the bacterium was suppressed by 80% or more compared to the control without drug. Also,AspergillusGenus fungi andTrichophytonThe genus fungi were visually determined, and the MIC was defined as the minimum drug concentration that inhibited the growth of the bacterium by 50% or more compared to the control without drug.
[0164]
The abbreviations in Table 4 refer to the following fungi and compounds.
C. alb:Candida albicans ATCC 90028
C. kru:Candida C. krusei ATCC 6258
A. fla:Aspergillus flavus IFM 41935
A. fum:A.fumigatus IFM 40808
T. men:Trichophyton mentagrophytes IFM 40769T. rub:Trichophyton rubrum IFO 6204
FLCZ: Fluconazole
[0165]
[Table 4]
[0166]
[Table 5]
[0167]
As is clear from Table 4, the compound (1) of the present invention shows excellent antibacterial activity against causative bacteria of deep mycosis and superficial mycosis, and particularly, a control drug against Aspergillus. Showed especially superior antibacterial activity than fluconazole. Moreover, as is clear from Table 5, the compound (1) of the present invention also showed excellent antibacterial activity against fluconazole-resistant bacteria.
[0168]
【The invention's effect】
The azole derivative or a salt thereof of the present invention exhibits excellent antibacterial activity against causative bacteria of deep mycosis and superficial mycosis, and an antifungal agent containing this as an active ingredient is useful for mammals including humans. It is useful for preventing and treating fungal infections.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003163358A JP2004359646A (en) | 2003-06-09 | 2003-06-09 | New azole derivative with antimycotic activity |
PCT/JP2004/007966 WO2004108684A1 (en) | 2003-06-09 | 2004-06-08 | Novel azole derivative having antifungal activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003163358A JP2004359646A (en) | 2003-06-09 | 2003-06-09 | New azole derivative with antimycotic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004359646A true JP2004359646A (en) | 2004-12-24 |
Family
ID=33508752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003163358A Pending JP2004359646A (en) | 2003-06-09 | 2003-06-09 | New azole derivative with antimycotic activity |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2004359646A (en) |
WO (1) | WO2004108684A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198429B2 (en) | 2011-11-25 | 2015-12-01 | Bayer Intellectual Property Gmbh | Heterocyclic alkanol-derivatives |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9102622B2 (en) * | 2006-07-28 | 2015-08-11 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
CA2837400C (en) | 2010-04-24 | 2017-12-12 | Viamet Pharmaceuticals, Inc. | 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors |
CA2800634A1 (en) * | 2010-05-27 | 2011-12-01 | Bayer Intellectual Property Gmbh | Heterocyclic alkanol derivatives as fungicides |
CA2800712A1 (en) * | 2010-05-27 | 2011-12-01 | Carl Friedrich Nising | Heterocyclic alkanol derivatives as fungicides |
EA025437B1 (en) | 2011-12-11 | 2016-12-30 | Ваймет Фармасьютикалс, Инк. | Metalloenzyme inhibitor compounds |
CN104356125A (en) * | 2014-10-27 | 2015-02-18 | 中国人民解放军第二军医大学 | Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof |
MX2018003357A (en) | 2015-09-18 | 2018-08-16 | Mycovia Pharmaceuticals Inc | Antifungal compound process. |
CN105237513B (en) * | 2015-11-26 | 2018-01-23 | 上海倚诺升生物医药科技有限公司 | A kind of trinitrogenazole alcohol heteroaromatic ether derivative and its preparation method and application |
AR109545A1 (en) * | 2016-09-29 | 2018-12-19 | Bayer Cropscience Ag | TRIAZOL DERIVATIVES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BG48681A3 (en) * | 1982-12-14 | 1991-04-15 | Ciba Geigy Ag | Fungicide means |
JPH06279419A (en) * | 1993-03-31 | 1994-10-04 | Tokyo Tanabe Co Ltd | New triazole derivative and antifungal agent containing the same derivative as active component |
-
2003
- 2003-06-09 JP JP2003163358A patent/JP2004359646A/en active Pending
-
2004
- 2004-06-08 WO PCT/JP2004/007966 patent/WO2004108684A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198429B2 (en) | 2011-11-25 | 2015-12-01 | Bayer Intellectual Property Gmbh | Heterocyclic alkanol-derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO2004108684A1 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5716969A (en) | Azolylamine derivative | |
IE910342A1 (en) | Triazole antifungal agents | |
JP4709148B2 (en) | Antifungal azole derivative having fluorovinyl group and process for producing the same | |
FR2542315A1 (en) | NOVEL AZOLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIFUNGAL AND FUNGICIDES | |
JPH07502022A (en) | triazole antifungal agent | |
JP2004359646A (en) | New azole derivative with antimycotic activity | |
HU194187B (en) | Process for producing triazol compounds and pharmaceutical compositions containing them | |
JP3415865B2 (en) | Optically active azole compound and use thereof | |
US4910213A (en) | Antimycotic agents | |
AU2012269895B2 (en) | Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation | |
TW438784B (en) | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same | |
US5059615A (en) | Antimycotically active cyclopropyl-substituted azolylmethylcarbinols | |
US5177094A (en) | Triazole compounds having antifungal properties | |
US5981560A (en) | Triazole antifungal agents | |
KR100381950B1 (en) | Triazole derivative or salt thereof, preparation process thereof and pharmaceutical containing said compound as an effective ingredient | |
JPH04356471A (en) | Triazole compound and its usage | |
AP875A (en) | Azole compounds with antimycotic activity for human and veterinary use. | |
JP3437695B2 (en) | Azolylamine derivative | |
NZ610143B2 (en) | Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation | |
JPH01102069A (en) | Antimycotic | |
JPH06340636A (en) | Triazole derivative or its salt and antimycotic agent containing the compound | |
JPH08253452A (en) | Production of optically active triazole derivative and its intermediate | |
JP2006347882A (en) | Benzyl alcohol derivative or salt thereof | |
IE904506A1 (en) | Azole compounds, their production and use | |
JPH0977750A (en) | New optically active triazole derivative or its salt, its production, antimycotic drug and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20050401 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050414 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060426 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100309 |